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Abstract 
 
The eye is a complex organ, which provides one of our most important senses, sight. The retina is 
the neuronal component of the eye and represents the connection with the central nervous system 
for the transmission of the information that leads to image processing.  
Retinitis pigmentosa (RP) is one of the most common forms of inherited retinal degeneration, in 
which the primary death of rods, resulting in night blindness, is always followed by the loss of 
cones, which leads to legal blindness. Clinical and genetic heterogeneity in retinitis pigmentosa is 
not only due to different mutations in different genes, but also to different effects of the same 
mutation in different individuals, sometimes even within the same family.  
My thesis work has been mainly focused on an autosomal dominant form of RP linked to mutations 
in the PRPF31 gene, which often shows reduced penetrance. Our study has led to the identification 
of the major regulator of the penetrance of PRPF31 mutations, the CNOT3 protein, and to the 
characterization of its mechanism of action.  
Following the same rationale of investigating molecular mechanisms that are responsible for 
clinical and genetic heterogeneity of retinitis pigmentosa, we studied a recessive form of the disease 
associated with mutations in the recently-identified gene FAM161A, where mutations in the same 
gene give rise to variable clinical manifestations. Our data have increased the knowledge of the 
relationship between genotype and phenotype in this form of the disease. 
Whole genome sequencing technique was also tested as a strategy for disease gene identification in 
unrelated patients with recessive retinitis pigmentosa and proved to be effective in identifying 
disease-causing variants that might have otherwise failed to be detected with other screening 
methods.  
Finally, for the first time we reported a choroidal tumor among the clinical manifestations of PTEN 
hamartoma tumor syndrome, a genetic disorder caused by germline mutations of the tumor 
suppressor gene PTEN. Our study has highlighted the heterogeneity of this choroidal tumor, 
showing that genetic and/or epigenetic alterations in different genes may contribute to the tumor 
development and growth. 
 
 

Résumé 
 
L'œil est un organe complexe, à l’origine d’un de nos sens les plus importants, la vue. La rétine est 
la composante neuronale de l'œil qui constitue la connexion avec le système nerveux central pour la 
transmission de l'information et qui conduit à la formation des images. 
La rétinite pigmentaire (RP) est une des formes les plus courantes de dégénérescence rétinienne 
héréditaire, dans laquelle la mort primaire de bâtonnets, entraînant la cécité nocturne, est toujours 
suivie par la perte de cônes qui conduit à la cécité complète. L’hétérogénéité clinique et génétique 
dans la rétinite pigmentaire n'est pas seulement due aux différentes mutations dans des gènes 
différents, mais aussi à des effets différents de la même mutation chez des individus différents, 
parfois même dans la même famille.  
Mon travail de thèse s’est principalement axé sur une forme autosomique dominante de RP liée à 
des mutations dans le gène PRPF31, associées souvent à une pénétrance réduite, me conduisant à 
l'identification et à la caractérisation du mécanisme d'action du régulateur principal de la pénétrance 
des mutations: la protéine CNOT3. 
Dans la même logique d'étude des mécanismes moléculaires responsables de l'hétérogénéité 
clinique et génétique de la RP, nous avons étudié une forme récessive de la maladie associée à des 
mutations dans le gène récemment identifié FAM161A, dont les mutations dans le même gène 
donnent lieu à des manifestations cliniques différentes. Nos données ont ainsi accru la connaissance 
de la relation entre le génotype et le phénotype dans cette forme de maladie. 
La technique de séquençage du génome entier a été ensuite testée en tant que stratégie pour 
l'identification du gène de la maladie chez les patients atteints de RP récessive. Cette approche a 
montré son efficacité dans l'identification de variantes pathologiques qui n’auraient pu être 
détectées avec d'autres méthodes de dépistage. 
Enfin, pour la première fois, nous avons identifié une tumeur choroïdienne parmi les manifestations 
cliniques du PTEN hamartoma tumor syndrome, une maladie génétique causée par des mutations 
germinales du gène suppresseur de tumeur PTEN. Notre étude a mis en évidence l'hétérogénéité de 
cette tumeur choroïdienne, montrant que les altérations génétiques et/ou épigénétiques dans les 
différents gènes peuvent contribuer au développement et à la croissance tumorale. 
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 Chapter 1  
 
 
 
 
 
Introduction 
 
 
The eye is a complex organ composed of different tissues and cell types that work in a coordinated 
manner to provide one of our most vital senses, sight. 
The retina is an essential component of the eye, since it represents the connection with the central 
nervous system for the transmission of information that leads to image processing.  
Among the neuronal cells that make up the retina, photoreceptors are the photosensitive cells that 
respond to different wavelengths of light providing both colour vision and vision in the dark. 
Despite reduction in the number of photoreceptor cells is a physiological process at old age, 
progressive death of these cells may be associated with hereditary degenerative disorders of the 
retina. 
 
The first chapter summarizes the anatomical organization of the various tissues in the eye with 
particular emphasis to the retina.  
Inherited forms of photoreceptor degeneration are introduced, and clinical and genetic features of 
one of the most common form, called retinitis pigmentosa, are described. 
Autosomal dominant retinitis pigmentosa with reduced penetrance linked to mutations in the gene 
PRPF31 is introduced in order to facilitate comprehension of chapter 2, which covers the main 
results obtained during my thesis work. 
Then, recessive forms of the disease associated with mutations in the recently identified genes 
FAM161A and MAK are presented in order to prepare for chapters 3 and 4. 
Finally, technical advances in massively parallel sequencing are discussed, with a particular 
emphasis to whole genome sequencing technique that has been used in chapter 5 as a strategy for 
disease gene identification in retinitis pigmentosa patients.  
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1.1 Anatomy and physiology of the human eye 
1.1.1 General anatomy of the eye 
 
The eye is one of the most perfect and complex organ of the human body. Its function is to process 
the light that is emitted or reflected from the surroundings objects allowing us to perceive the 
shapes and colours of objects.  
In the human eye we can distinguish three different anatomical structures, called tunics [1-2] 
(Figure 1):  
- The fibrous tunic is the outermost layer, which is composed by the cornea and the sclera. 
The cornea is a transparent layer, while the sclera is a collagen-rich connective tissue, which 
gives the white colour to the eye and supports the eyeball shape. 
- The vascular tunic is the central layer, which is formed by the choroid, the ciliary body and 
the iris. The choroid is a connective tissue that provides nourishment and oxygen to the 
retinal cells. The ciliary body is responsible for the production of the aqueous humor, which 
is vital for the maintenance of normal intraocular pressure and to bring nutrients to the lens 
and the cornea. The iris is the diaphragm of the eye, with the pupil being its central opening; 
it also regulates the flow of fluid inside the eye. 
- The nervous tunic is the innermost layer, which is constituted by the retina, the essential 
component of the eye for the process of photoreception.  
 
 
    
                 Source: www.laramyk.com 
Figure 1. Simplified anatomy of the human eye. 
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The shape of the eye is not exactly that of a sphere, but rather that of two combined spheres, a 
smaller and more curved one at the front and a larger and less curved one in the back.  
The anterior part of the eye is constituted by the cornea, the iris, the ciliary body and the lens, while 
the posterior part is composed by the vitreous humor, the retina, the choroid, and the optic nerve 
(Figure 1).  
The size of the eye is rather constant, varying only 1-2 millimetres among humans; the average 
vertical diameter of a human eye is 24 millimetres, which is usually smaller than the transverse 
diameter.  
The lens is a transparent avascular structure that is semi-permeable to water and electrolytes. Since 
the depth of field of the mammalian eye is limited, the curvature of the lens needs to be adjusted so 
that, in order to focus on nearby objects, the lens becomes thicker and rounder, while for distant 
objects it gets flatter. This process is known as accommodation, and the ability of the lens to 
accommodate for near objects decreases with age [2] (Figure 2).  
 
 
 
 
Source: zeiss-campus.magnet.fsu.edu 
Figure 2. Accomodation of the human eye. 
 
 
Light coming from an object first encounters the cornea, which allows light to enter the eye and to 
proceed through the pupil that can adapt to different intensities of light by changing its dimensions; 
in case of bright light the pupil gets smaller, while it dilates in dark conditions. Behind the pupil the 
 8 
light waves converge on the lens, where the image is turned backwards and upside-down (Figure 2). 
Through the vitreous humor, a transparent gel that constitutes almost the 80% of the total volume of 
the eye, the light finally is focused on the retina. Within the different retina layers light is processed 
into electric signals that are then sent through the optic nerve to the occipital cortex of the brain, 
where they are elaborated as a visual image. 
 
The retina is the innermost tissue of the eyeball, which surrounds the vitreous cavity and is 
protected and kept in its correct location by the sclera and the cornea.  
It is the neural tissue of the eye and actually a component of the central nervous system despite its 
peripheral location [3]. 
In the retina we can distinguish five major types of neurons: photoreceptors, bipolar cells, amacrine 
cells, horizontal cells and ganglion cells.  
Retinal neurons are arranged in parallel layers, three of which consist of neuronal-cell bodies and 
two are synaptic layers (Figure 3): 
- The outer nuclear layer (ONL) contains the nuclei of photoreceptor cells.   
- The outer plexiform layer (OPL) is where photoreceptors interact with bipolar and 
horizontal cells. 
- The inner nuclear layer (INL) contains the nuclei of amacrine, horizontal and bipolar cells. 
- The inner plexiform layer (IPL) is where bipolar and amacrine cells interact with synapses 
of ganglion cells. 
- The ganglion cell layer (GCL) contains the nuclei of ganglion cells. 
- The nerve fiber layer (NFL) is where there are the axons of ganglion cells. 
Overlying all these layers there is the retinal pigment epithelium (RPE), which is composed of 
hexagonal cells interacting with the choroid on one side and with photoreceptors on the other. 
The RPE provides nourishment and support to the photoreceptors, as well as eliminates their 
metabolic wastes by phagocitosis.  The latter represents a major task considering that photoreceptor 
discs in their outer segment are replaced every 12 days [3]. In addition, the RPE is even able to 
regenerate the photopigments (the pigments involved in photoreception) after they have been 
exposed to light [3]. 
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Source: Purves et al. [3] 
 
Figure 3. Cross section of the retina with the retinal layers. 
 
 
In the retina of most vertebrates there are two types of photoreceptor cells, rods and cones, which 
are structurally similar, but respond to different light intensities and are differentially distributed in 
the retina.  
Both cells have an outer segment where photopigments are accumulated within membranous discs 
and which is in contact with the RPE, and an inner segment, which contains the cell nucleus, and 
from where the synapses that then make contacts with bipolar and horizontal cells derive [3]. 
Cones are mainly located in the fovea, a dip in the macula (the central part of the retina), directly 
behind the lens, which is responsible for sharp central vision due to the largest concentration of 
cones there. Rods are not present in the fovea, but are mostly distributed at the outer edges of the 
retina. 
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There are three different types of cones (S, M, and L cones) that respond to different wavelengths of 
light to provide colour vision.  
Higher visual acuity of cone cells depends on the fact that each of them makes contact with a single 
bipolar cell, while several rod cells interact with a single bipolar cell (Figure 3).  
Rods are conversely highly more sensitive than cones to photons of light and are responsible for 
vision in dark conditions, but do not provide colour vision.  
In the human retina there is also a third small class of photosensitive cells, represented by the 
intrinsically photosensitive retinal ganglion cells (ipRGCs). Unlike photoreceptors, they are 
probably not involved in vision, but regulate circadian rhythms of light-dark cycles, control the 
pupillary light responsiveness, and the light-regulated melatonin release by the pineal gland [4]. 
 
 
1.1.2 Physiological processes in the eye 
 
The process through which the light is converted into biological signals within the retina is called 
phototransduction. In daylight conditions photoreceptors respond to light thanks to the 
photopigments they contain in their outer segment discs [5] (Figure 4). 
These molecules are constituted by a cell membrane protein, called opsin, and the retinal, a 
chromophore derived from vitamin A that is reversibly bound to it. In both rods and cones the 
chromophore is the same but the protein moiety changes. Rod photopigment is called rhodopsin, 
while cones have three different opsins that are able to absorb light with short, medium and long 
wavelengths. 
Light isomerizes the retinal from an 11-cis to an all-trans conformation, leading to separation of the 
retinal from the opsin. Through the activation of a cascade of proteins, the second messenger cyclic 
guanosine monophosphate (cGMP) is hydrolized, the ion channels on the photoreceptor membranes 
are closed,  thus the membrane hyperpolarizes to -70mV, leading to a decrease in the release of the 
neurotransmitter glutamate [5-6] (Figure 4).  
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Source: faculty.pasadena.edu 
 
Figure 4. Phototransduction in rods. 
 
 
Subsequently, the all-trans retinal and the intermediate of opsin are transformed back into 11-cis 
retinal and opsin (Figure 4). 
Conversely, under dark conditions, the cGMP is accumulated in the discs of photoreceptor cells 
where it allows the influx of cations, especially sodium, through the ion channels, which in turn 
leads to a constant release of glutamate onto bipolar neurons  [7] (Figures 4 and 5).  
The main route through which information passes from the photoreceptors to the optic nerve is the 
direct contact between three types of neurons (photoreceptors to bipolar cells to ganglion cells) [3] 
(Figure 3). Bipolar cells respond to the chemical signal coming from the photoreceptors through 
different glutamate receptors [7] (Figure 5). The OFF-center bipolar cells have excitatory synapses 
with photoreceptor cells, while the ON-center bipolar cells have inhibitory synapses. These parallel 
bipolar cell channels allow us to perceive the contrast between images and their background [7].  
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Source: what-when-how.com/neuroscience 
 
Figure 5. Response properties of bipolar and ganglion cells to light and dark conditions. 
 
 
Two types of ganglion cells communicate with ON- and OFF-center bipolar cells: the ON-center 
ganglion cells that are activated by light targeting the center of their receptive field and the OFF-
center ganglion cells that are activated by light targeting the periphery of their receptive field [7] 
(Figure 5).  
Lateral interactions within the retina are indeed mediated by two other types of neurons, the 
horizontal and amacrine cells, whose cell bodies are located in the INL [3] (Figure 3).  
The axon terminals of horizontal cells interact with photoreceptor cells, producing a surround effect 
that enhances brighter contrast depending on the background (Figure 3). 
Amacrine cells make contacts with bipolar and ganglion cells, providing not only lateral but also 
vertical connections between cells (Figure 3).  
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1.2 Inherited and multifactorial forms of photoreceptor degeneration 
 
In the retina of a healthy individual loss of photoreceptor cells with age is a physiological 
mechanism, with an average of 30% of cell death in a 80-year-old person [8].  
Pathological photoreceptor degeneration indeed can be considered as a complex trait, since it is 
caused not only by mutations in different genes, but also by the contribution of environmental 
factors [9].  
Despite not being a homogeneous group of diseases, photoreceptor degenerations have in common 
that the primary or secondary event leading to loss of vision is the premature death of photoreceptor 
cells [9].  
Inherited forms of photoreceptor degeneration (except AMD) are usually monogenic and rare 
disorders (minor allele frequency < 0.01), having an average prevalence of 1/3000 individual 
(reviewed in [9]). 
 
Retinitis pigmentosa (RP) is the most common type of retinal degeneration, affecting approximately 
1/4000 individual worldwide (reviewed in [10-12]). It is a clinically and genetically highly 
heterogeneous disease, whose initial feature is poor night vision due to rod dysfunction in early or 
middle life, which invariably leads to a secondary cone dysfunction. 
 
Leber congenital amaurosis (LCA) is the most severe form of retinal degeneration, with 
photoreceptors that are lost within the first years of life, or are already dead at birth. Different 
mutations in genes that cause LCA can also be responsible for the pathogenesis of RP and other 
retinal dystrophies, depending on the severity of the variants.  
 
Cone degenerations are not uncommon forms in which all three types of cones are lost, while rods 
are preserved. The end stage of the disease is rod monochromacy, known as achromatopsia, that is 
when exclusively rods mediate vision.  
 
Cone-rod degenerations are characterized by the primary degeneration of cones, followed by the 
secondary loss of rods. Retinal pigment deposits are present predominantly in the macula. 
Decreased visual acuity and colour vision defects appear in the early stages, followed by loss of the 
peripheral vision and night blindness in the later stages. The clinical course of the disease is usually 
more severe and rapid than the one observed in rod-cone degenerations.  
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Inherited macular degenerations represent a large number of relatively rare retinal degenerations 
that affect photoreceptor cells in the macula. They usually occur at early to middle age and are 
characterized by gradual loss of visual acuity, colour vision and contrast sensitivity [13].  
 
Inherited retinal degenerations can occur alone or even in the context of more complex syndromes 
that present extra-ocular manifestations.  
Usher syndrome is the most frequent form of syndromic retinitis pigmentosa, where early or 
congenital hearing impairment is associated with early onset RP [11, 14]. According to the type of 
mutation, some genes that cause Usher syndrome can cause either only retinitis pigmentosa or 
hearing loss [15-16]. 
Bardet-Biedl syndrome is another syndromic form of RP, whose clinical features, such as obesity, 
polydactyly, hypogenitalism, cognitive impairment, and renal disease, are variably associated with 
retinitis pigmentosa. The inheritance pattern is usually autosomal recessive, even if in some families 
compound heterozygosis or homozygosis at one gene locus has been found together with a 
heterozygous mutation at a second gene locus, which is indicative of triallelic-digenism (reviewed 
in [11, 17]). 
 
Most of the genes that contribute to the inherited forms of photoreceptor degeneration account only 
for a small fraction of cases and these are essential genes not only for photoreceptor-specific 
functions, such as the visual cycle and phototransduction, but also for general cellular functions, 
such as mRNA splicing, protein degradation, and many others (Figure 6).  
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Source: Wright, A.F. et al [9] 
 
Figure 6.  Pathways responsible for photoreceptor degeneration.  
 
 
Among the multifactorial form of photoreceptor degeneration age-related macular degeneration 
(AMD) represents the leading cause of blindness in the Western countries, with a prevalence that 
rises exponentially with age [9]. Typical features of the disease are lipid and protein deposits, called 
drusen of the macula, that lead to macula degeneration. There are two distinct manifestations of the 
disease, a dry form and a wet form due to abnormal blood vessels into the macula. Several studies 
have shown that AMD is a complex trait, with multiple susceptibility genes and environmental 
factors that could contribute to the risk of developing the disease, but monogenic forms could be 
rare (reviewed in [9]). 
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1.3 Retinitis pigmentosa 
1.3.1 Clinical and pathological features 
 
Retinitis pigmentosa is the most common inherited form of photoreceptor degeneration, which is 
characterized by pigmented deposits in the periphery of the retina, and by a primary degeneration of 
rod photoreceptors.  
The course of the disease often involves several decades, even if there are exceptional cases of rapid 
evolution or of very slow progression of the disease.  
 
The electroretinogram (ERG) is a powerful tool to measure the electrical responses of the retina to 
standardized stimuli (flashes of light), and it is routinely used for the diagnosis of various retinal 
diseases, included RP [18]. A single dim blue light flash stimulates a rod response, a single brighter 
white light flash stimulates a rod-cone response, and a flickering white light stimulus enhances a 
cone response. With single flashes of white light there is first a hyperpolarization of the 
photoreceptors (represented by the a wave), followed by the depolarization of the same cells 
(represented by the b wave) (Figure 7). Patients with retinitis pigmentosa show reduced amplitude 
of both rod and cone responses, as well as a delayed timing [19] (Figure 7). The clinical usefulness 
of ERG for RP patients is not only in detecting individuals with retinitis pigmentosa within a 
family, but especially in identifying healthy relatives of affected subjects. The results obtained from 
studies of siblings in families with RP show that ERG results follow Mendel’s law of inheritance 
[12].  
 
Optical coherence tomography is another technique that can be useful for evaluating the retinal 
morphology, in particular to look at the photoreceptor cell layer without being invasive [20]. 
Usually the remaining photoreceptors in RP patients present a shorter outer segment but have an 
intact cell body. Despite being reduced in cell number and having a reduced quantity of visual 
pigments they are therefore still functional [12]. 
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Source: Hartong, D.T. et al [11] 
 
 
Figure 7.  ERG responses in a healthy individual and in RP patients with different mode of 
inheritance. 
 
 
 
In early RP stages patients first complain about night blindness, and ERG could reveal decreased 
amplitude of the b-wave that originates in retinal cells that are post-synaptic to the photoreceptors 
under low light conditions (the so called scotopic vision) [10, 12].  Anomalies in ERG responses 
can even be detected years before the onset of clinical symptoms [12]. 
In this early phase of the disease, retinal pigments are usually not yet present, and visual acuity and 
colour vision are normal [11-12] (Figure 8).  
 
In mid RP stages patients experience the loss of peripheral visual field in daylight conditions, a 
reduction in cone sensitivity, and possibly macular involvement (i.e. macular edema) [12]. Cataracts 
is often present, together with refractive errors, like myopia and astigmatism [12]. Bone-spicule-
shaped pigment deposits appear at this stage in the mid periphery, along with atrophy of the retina, 
and can be revealed by fundus examination [10-11] (Figure 8). These pigment deposits originate 
from the retinal pigment epithelium that invades the neural retina in response to photoreceptor cell 
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death [11]. ERG at this stage does not record any response from rods in scotopic conditions, while 
cone responses are hypovolted [10]. 
 
 
 
 
Source: Hamel, C. [10]  
 
Figure 8.  Fundus examination of an RP patient, from early to mid and end stage (panels from 
the left to the right). 
 
 
In end RP stages peripheral vision is completely lost (classical tunnel vision) and fundus 
examination shows that pigmentation has invaded even the center of the retina, retinal vessels 
became thin and the optic disc is pale [10-12] (Figure 8). At this stage ERG is unrecordable.  
Visual acuity may be normal even in the later stages of the disease, when only a small part of the 
visual field is preserved and ERG amplitudes are very low, or can be lost very early [11].  
 
1.3.2 Genetic causes 
 
Non-syndromic forms of RP are usually monogenic disorders that are transmitted by classical 
inheritance patterns (reviewed in [17]) (Figure 9): 
- Autosomal dominant forms are the mildest, and can present variable penetrance and 
expressivity in the forms linked to mutations in PAP-1, PRPF31, PRPF8, BRR2, and RP1 
genes [21-23]. 
- Autosomal recessive forms are usually more severe and appear earlier, often during the first 
decade of life.   
- X-linked forms are frequently associated with myopia and start early in life [10]. The way of 
inheritance is mostly recessive, but they can also be inherited in a dominant way, 
characterized by the presence of affected females [10]. ERG testing can help to identify 
female carriers of X-linked retinitis pigmentosa, since ERGs from obligate carriers are 
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reduced in amplitude or delayed in implicit time or both [24]. Being able to distinguish X-
linked forms from recessive forms of the disease has important clinical implications, since 
males affected by X-linked RP become legally blind by ages 30-45, while males with 
recessive forms are usually legally blind by ages 45-60 [12]. 
- Digenic-diallelic forms are characterized by the presence of affected individuals that are 
heterozygous for mutations in two unlinked genes. The way of inheritance resembles in the 
first affected generation a recessive pattern, while in the subsequent generations mimics a 
dominant pattern with a 25% risk of affected offspring [25]. The first example of digenic 
inheritance in RP was that of RDS and ROM1 genes [25]. 
Among non-syndromic cases dominant RP represents roughly 30% of the cases, recessive RP 20% 
of the cases, and X-linked RP 15% of the cases. The remaining cases are mostly isolate or de novo 
mutations (reviewed in [26]).   
 
 
 
 
Source: modified from Rivolta C. et al. [17]  
 
Figure 9.  Retinitis pigmentosa mode of inheritance. 
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Most genes involved in the pathogenesis of RP cause exclusively one genetic subtype of the 
disease, but some others, like the transcription factor NRL, can be responsible for both dominant 
and recessive forms of RP [27-28].  
 
The majority of genes that cause RP are responsible only for a minority of cases, with the exception 
of RHO, which was the first RP gene to be identified [29-30], that accounts for about 25% of 
dominant RP cases in the U.S., USH2A, which causes about 20% of recessive RP cases, and RPGR, 
which alone explains about 70% of X-linked RP cases [11].  
To date, according to RetNet – the Retinal Information Network (https://sph.uth.edu/retnet/, last 
updated February 2013), there are 50 genes and loci that have been shown to be responsible for 
non-syndromic RP, including 19 genes/loci for autosomal dominant, 26 for autosomal recessive, 
and 5 for X-linked forms. Most of the genes are appointed to photoreceptor-specific functions, but 
there are also others that are essential for more general cellular functions, suggesting that 
photoreceptors may have a higher metabolic requirement compared to other cell types in order to 
elicit their functions [31]. The high energy consumption of the photoreceptor cells may require an 
intense mRNA and protein synthesis, thus if one of these cellular mechanisms stops functioning at 
full capacity the photoreceptors undergo apoptosis. 
The genes that have been associated with the pathogenesis of RP to date account only for about 50-
60% of the cases, suggesting that there is still much to do to discover the missing genetic causes of 
the disease. There can be several explanations for such a percentage of unsolved cases: first, novel 
mutations in known RP genes, as well as genomic rearrangements or deletions, could fail to be 
detected by conventional screening approaches; second, there are for sure additional unknown RP 
genes that will be possibly identified within the next years by high-throughput sequencing 
techniques. Discover the genetic causes of such a heterogeneous disease will help not only for 
family counselling and to assess the risk of recurrence, but also in view of gene-specific therapies to 
be developed.  
 
 
1.3.3 Therapeutic approaches 
 
Different therapeutic strategies are aiming to slow the progression of the disease or even restore 
vision to patients: 1) nutritional treatments; 2) gene-specific approaches; 3) treatments that affect 
secondary biochemical pathways; 4) transplantation; 5) implanted electrical devices. 
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Clinical trials to assess the effectiveness of strategies based on supplementation of vitamin A to 
patients affected by different forms of RP revealed so far a slower decline in cone ERG amplitudes 
and a slower loss of visual field in patients who followed the diet compared to those who did not 
take the supplement [32-34]. Based on these findings some doctors recommend to adult patients in 
the early or mid stages of the disease a daily dose of oral vitamin A (retinyl palmitate 15000 IU/d). 
Toxic effects due to the supplementation in the diet of vitamin A have been reported; in particular 
the treatment can increase the risk of birth defects in pregnant women and of fractures in older 
individuals [35-37].  
Additional nutritional treatment for RP is docosahezaenoic acid (DHA), an omega-3 fatty acid that 
is highly present in oily fish and in the photoreceptor cell membranes. Despite initial studies did not 
show a clear benefit with this treatment, following studies in larger cohorts of patients could show 
that a combined vitamin A and omega-3-rich diet can not only slow the rate of decline of ERG and 
visual field, but also retain visual acuity [34, 38-40]. Omega-3 can help the delivery of vitamin A 
from rods to cones via Müller cells, providing a possible explanation of how combination of 
vitamin A and omega-3-rich diet can rescue the remaining cones in patient with RP [41].  
 
Gene-specific therapeutic approaches are highly depending on the type of mutation to be targeted. 
Null mutations are usually responsible for the recessive forms of the disease and represent the ideal 
target for gene-replacement since the normal copy of the gene is lost. Mutations that are responsible 
for dominantly inherited forms are typically producing an aberrant transcript that can be toxic for 
the cell; in such cases one strategy is to reduce or eliminate the expression of the mutant copy of the 
gene. In several animal models with dominant and recessive forms of RP gene-replacement and 
silencing were shown to be effective strategies to restore vision, but there are still many difficulties 
before these techniques can be applied to humans (reviewed in [42-45]). One limitation is that 
patients may have lost all or almost all rod cells, therefore the therapeutic approach would be rather 
aiming at the preservation of the few remaining cone cells. Gene-therapy looks particularly 
promising in the treatment of one form of Leber’s congenital amaurosis (LCA), which is caused by 
recessive mutations in the RPE65 gene, a retinal isomerase involved in the phototransduction 
cascade. Proof of concept that gene-therapy could represent an effective strategy for the treatment 
of this form of the disease came from studies in the Briard dog, a naturally occurring animal model 
for RPE65-linked form of LCA [46-50]. Later, independent clinical trials in humans, performed by 
subretinal delivery of a recombinant adeno-associated virus carrying RPE65 complementary DNA 
(cDNA) in patients with severely advanced LCA, could show an improvement in visual function 
and no detectable side effects in the short term [51-53]. 
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Neurotrophic factors are proteins that are responsible for the growth and survival of developing 
neurons and the maintenance of mature neurons. In the treatment of retinal degenerative diseases 
they represent a therapeutic approach that is independent of the aetiology of the disease. Their effect 
is to protect the integrity of photoreceptors by preserving their environment. In RP animal models 
several factors that can slow photoreceptor death by acting on secondary biochemical pathways 
have been identified (reviewed in [54-55]). Basic fibroblast-derived growth factor (bFGF) has been 
extensively investigated since the nineties, but has never been introduced in the clinic because of 
the problems related to its delivery to the retina and to side-effects [54]. Ciliary neurotrophic factor 
(CNTF) has been shown to reduce photoreceptor degeneration in RP animal models [56]. The first 
phase of a clinical trial in patients was well tolerated [57], although it has not yet been proven that 
the treatment is improving photoreceptor function in patients with RP [58].  
 
Transplantation of retinal pigment epithelial cells, photoreceptors, or stem cells looks at the moment 
a very promising approach to treat retinal degenerations [59-62]. 
 
Implanted devices to electrically stimulate the retina have been developed and tested in animals and 
humans. Recently, the U.S. Food and Drug Administration has approved the first artificial retinal 
implant to help restore vision in people affected by RP [63]. 
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1.4 Clinical and genetic heterogeneity in retinitis pigmentosa 
 
Clinical and genetic heterogeneity in retinitis pigmentosa is not only due to different mutations in 
different genes, but also to different effects of the same mutation in different individuals, sometimes 
even within the same family [12, 26]. 
 
1.4.1 Autosomal dominant forms with reduced penetrance 
 
In medical genetics, penetrance refers to the proportion of individuals with a particular variant of a 
gene that develops the clinical manifestation of the disease. 
Transmission of the disease through at least three consecutive generations in a branch of a family is 
a prerequisite for the autosomal dominant forms of retinitis pigmentosa. Skipping of symptoms in 
one or two generations has been early described in some families with autosomal dominant RP 
(adRP), indicating reduced penetrance [64-67]. Asymptomatic obligate carriers show no impaired 
vision and normal to slightly reduced electroretinographic recordings, and remain unaffected even 
after many years of follow-up [64-65] (Figure 10).  
 
 
 
 
 
 
 
 
 
 
                                
 
 
Source: Adapted from Berson and Simonoff [65] 
 
 
Figure 10.  In some pedigrees autosomal dominant RP displays reduced penetrance.  
The asymptomatic individual is represented by the black dot. ERG of the affected patient is flat, whereas the 
asymptomatic patient shows an ERG only reduced in amplitude. 
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A clinical feature of the dominant forms of RP showing incomplete penetrance is that the affected 
individuals of such families show, together with an early involvement of the rod cells, a delayed in 
implicit time of the cone system [64]; since their visual field is still preserved and they retain a good 
visual acuity this abnormality probably derives from an abnormal function of the extrafoveal cones 
[65]. 
 
Linkage analysis in families with dominant RP with reduced penetrance showed an association of 
the responsible disease gene, called RP11, with markers within chromosome 19q13.4 [68-71]. 
Patients from these pedigrees show bimodal expressivity defined by the presence of complete 
asymptomatic individuals who have both affected parents and affected children [72-73]. 
In 2001, mutations in the gene PRPF31, homologous to Saccharomyces cerevisiae pre-mRNA 
splicing gene Prp31 [74], were reported in families with autosomal dominant RP linked to the RP11 
locus [75].  
The PRPF31 gene comprises 14 exons and encodes a protein of 499 amino acids, among which a 
nuclear localization signal and a Nop domain (a ribonucleoprotein binding module, exhibiting RNA 
and protein binding surfaces) have been identified. As demonstrated by PCR analysis of cDNAs 
from a variety of normal tissues and in agreement with data from the EST database 
(http://www.ncbi.nlm.nih.gov/unigene), PRPF31 is ubiquitously expressed in the human body [76]. 
As previously mentioned, PRPF31 encodes for a protein that is a component of an essential cell 
machinery, the spliceosome. Removal of intron sequences by splicing occurs by two sequential 
trans-esterification reactions that are catalyzed by the components of this large RNA-protein 
complex [77]. 
The formation of the major spliceosome complex involves the stepwise assembly of four small 
nuclear ribonucleoprotein particles (snRNP U1, U2, U4/U6, and U5) and many non-snRNP splicing 
factors on a pre-mRNA. The U4/U6.U5 tri-snRNP is one of the major components of the 
spliceosome. Three splicing factors (PRPF3, PRPF8, and PRPF31), whose mutations have been 
associated with adRP, were shown by yeast two-hybrid screening to be part of the tri-snRNP 
complex [78] (Figure 11). PRPF31 is a critical component of the spliceosome for the formation and 
the stability of the tri-snRNP [79-80], in addition to being essential for cell survival, as 
demonstrated by repressing its expression by RNAi, which finally leads to cell death by apoptosis 
[81]. In the U4/U6 di-snRNP it binds to the U4 snRNA [82] and forms a bridge between this di-
snRNP and the U5 snRNP by specifically interacting with the U5-specific protein, PRPF6 [79] 
(Figure 11). 
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Source: Liu et al. [78] 
 
Figure 11. Schematic representation of the tri-snRNP composition. Black dots indicate interactions.  
 
 
PRPF31-linked autosomal dominant RP accounts for about 5% of adRP cases [11, 83] and, so far, 
the prevalence of frameshift mutations suggests that the pathophysiological basis of adRP linked to 
this locus is the functional loss of one allele, resulting in haploinsufficiency [84-87]. 
To date, over 40 mutations have been identified (reviewed in [85]), including frameshift, nonsense, 
missense, and splice site mutations, and recently even a single-base pair mutation in the promoter 
region of PRPF31 has been described [88]. 
Previous linkage studies have demonstrated that the penetrance of PRPF31 mutations would be 
determined by alleles, inherited from the parent who does not carry any PRPF31 mutation, located 
within or close to the PRPF31 locus itself [70, 75]. The refined chromosomal region containing 
these alleles corresponds to a 1.4 Mb region on chromosome 19q13.4, between polymorphic 
markers D19S572 and D19S926 [70]. These particular alleles, named isoalleles, do not produce any 
phenotype by themselves but in trans with respect to a mutation they determine whether or not the 
mutation will produce retinal degeneration [70]. The molecular basis of these isoalleles remains 
unknown, but evidence for such isoalleles comes from the study of 26 sib pairs from 4 different 
families with PRPF31-linked adRP [70]. In this meta-analysis, 10 sib pairs with the same 
phenotype (affected or asymptomatic) have inherited the same wild type PRPF31 allele from the 
noncarrier parent and, on the opposite, 13 sib pairs with different phenotypes have inherited 
different haplotypes. However, 3 sib pairs with discordant phenotypes have been found to carry 
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identical wild type haplotypes. These data indicate that these isoalleles are probably the major 
modulators of the penetrance of PRPF31 mutations but other modifiers could play a role as well. 
Another genetic element potentially capable of influencing the penetrance of PRPF31 mutations 
was later mapped to chromosome 14q21-23 [89]. 
To investigate whether the incomplete penetrance phenotype characteristic of PRPF31-linked adRP  
was due to differentially expressed wild-type alleles in asymptomatic and affected individuals, 
levels of PRPF31 wild type mRNA were measured in lymphoblastoid cell lines derived from 
patients from one British [90] and six American [91] adRP families, each with a distinct PRPF31 
mutation (Figure 12). Even though the methods used for evaluating mRNA levels differed between 
the two studies the results were similar, indicating that there is a correlation between the wild type 
mRNA level and the clinical status. In particular, non-carriers of PRPF31 mutation have 
significantly more PRPF31 wild type mRNA than affected patients, and asymptomatic carriers of 
the mutation express an intermediate level (Figure 12).  
PRPF31 protein quantification confirmed the mRNA data [90], suggesting that the clinical 
manifestation of the disease in these families is probably due to the low expression of PRPF31 
wild-type allele in trans with the mutant allele.  
The variable expression of PRPF31 seems to be even present within the general population and 
therefore asymptomatic carriers of the mutation would be individuals that by chance are “high 
expressors” of the PRPF31 wild-type allele [89].  
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Sources: Vithana et al.[90] and Rivolta et al. [91] 
 
 
Figure 12. PRPF31 mRNA expression levels in affected, asymptomatic patients and in controls.   
On the left side scatter plot showing PRPF31 mRNA copy numbers in symptomatic (S), asymptomatic (AS), 
and noncarrier (N) individuals of the AD5/RP856 pedigree [90]. On the right side PRPF31 mRNA levels 
obtained integrating data from Affimetrix and CodeLink microarrays and real-time PCR experiments [91].  
 
 
Studies in humans, aimed at linking mutations in this ubiquitously expressed gene and a retina-
specific disease failed to prove the existence of retina-specific PRPF31 isoforms [76]. A more 
convincing hypothesis seems to be the uniquely high demand for RNA processing and protein 
synthesis in the retina, mainly due to the continuous renewal of rod outer segments. Despite 
heterozygous PRPF31 mutations have been shown to cause a generalized impairment of splicing 
activity, most human tissues, with the exception of the retina, are probably able to tolerate them [31, 
92].  
PRPF31 animal models have not provided conclusive answers to this issue. Two PRPF31 targeted 
mouse models have been developed so far: one is a heterozygous knock-in mouse that carries a 
point mutation that was previously identified in adRP patients (Prpf31A216P/+), while the other is an 
heterozygous knock-out mouse (Prpf31+/-) [93]. After up to 18 months neither of them developed a 
perceptible RP phenotype [93]. Both homozygous mice are indeed embryonic lethal, indicating that 
no other protein or mechanism is able to compensate for Prpf31 loss [93]. Only the ultrastructural 
characterization of the heterozygous Prpf31+/- mouse model at one year of age allowed showing 
some degenerative changes in the RPE cells, suggesting that these may be the primary cell type 
affected in the splicing factor forms of RP. Two other knock-in mouse models targeting Prpf3 and 
Prpf8 presented similar results at 2 years of age [93-94]. Moreover, the late onset phenotype 
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observed in mice can be consistent with the adult onset phenotype observed in several patients with 
splicing factor forms of RP [94].    
PRPF31 associated RP has been also modelled in zebrafish [95-96].  
 
1.4.2 Autosomal recessive forms 
 
Autosomal recessive retinitis pigmentosa (arRP) comprises a group of disorders, which includes 
juvenile and early-onset forms, whose symptoms may overlap with other autosomal recessive 
retinopathies. To date more than 30 genes and loci have been associated with arRP (RetNet 
database; https://sph.uth.edu/retnet/sum-dis.htm), and some of them are known to be responsible for 
LCA as well. However, the sum of the frequencies of these genes does not explain more than a third 
of the cases of arRP, since the majority of them contribute to less than 1% of cases and only few are 
responsible for more than 10% of cases (reviewed in [11, 26]). From the clinical point of view 
autosomal recessive forms start usually during the first decade, although there may be also milder 
forms [10].   
 
The RP28 locus associated with arRP has been mapped in the past to chromosome 2p14-p15 by the 
analysis of a consanguineous Indian family [97].  
Most of the genes contained within this locus were expressed in the eye or in the retina, but not 
many of them were good candidates for the disease. MDH1 was chosen via a classical candidate 
gene approach, but was excluded as the possible cause of RP28-linked arRP since no mutation was 
found [98]. The RP28 disease-causing gene, named FAM161A, was finally identified thanks to two 
different methodological approaches, homozygosity mapping in consanguineous Israeli and 
Palestinian families and a combination of ultrahigh-throughput sequencing and gene expression 
experiments [99-100].  
FAM161A is a well-conserved protein among vertebrates, and despite having multiple splicing 
variants, only two of them produce stable mRNA transcripts in humans (Figure 13). The main 
splicing isoform contains six exons and encodes for a protein of 76 kDa, while the second transcript 
contains a supplementary 168 bp in-frame exon between exons 3 and 5 (Figure 13). Both encode 
proteins that contain a single domain, called Pfam UPF0564, of unknown function.  
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Sources: Bandah-Rozenfeld et al. [99]  
 
 
Figure 13. Presence of FAM161A alternative isoforms in human retinal cDNA.  The major isoform 
FAM161A_001 does not contain exon 4, while the less expressed transcript FAM161A_005 harbours the 
alternative exon. 
 
 
The major isoform shows expression limited only to the human retina and testis [100].  
In mice, Fam161a is highly expressed in the developing and adult retina and its expression is driven 
by the transcription factor Crx [100].  Recently, FAM161A was shown to localize to the ciliary 
region, linking photoreceptor outer and inner segments [101-102], and to interact with other ciliary 
and ciliopathy-associated proteins [102], but its exact function is still unknown. 
In the German cohort analyzed by Langmann et al. the prevalence of FAM161A-associated RP was 
in the range of 2-3%, comparable to that of other arRP genes [100]. However, in the Israeli and 
Palestinian populations FAM161A is the most frequently mutated gene in patients with arRP [99] 
(Dr. D.Sharon, personal communication).  
From the clinical point of view, patients with FAM161A mutations display symptoms ranging from 
an atypically late-onset form of RP, detected in the German cohort, to an early-onset manifestation 
of the disease, observed in the Israeli and Palestinian individuals [99-100]. Unexpectedly, despite 
these clinical differences, all patients carry mutations that lead to loss-of-function of the encoded 
protein. 
 
 
The male germ cell-associated kinase (MAK) is a serine/threonine protein kinase encoded in 
humans by the gene MAK, which is located on the short arm of chromosome 6. This highly 
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conserved protein contains a MAP kinase (mitogen-activated protein kinase) domain in its N-
terminal end, and its expression is restricted only to the testis and the retina [103-104]. Both in 
mouse and human retina there is a longer MAK isoform that contains an alternative 75-bp exon 
between exons 11 and 12, which seems to be photoreceptor-specific [105-107] (Figure 14).  
In mouse, Mak regulates retinal photoreceptor ciliary length and seems to be crucial for long-term 
survival of photoreceptors, since Mak-/- mice develop progressive retinal degeneration [105]. 
Recently, mutations in MAK have been associated with arRP [106-107]. A homozygous insertion of 
a 353-bp Alu-element in exon 9 has been described in an isolated RP patient with Jewish ancestry 
[107]. In retinal cells derived from the patient this mutation was proven to prevent the retina-
specific isoform to be expressed [107].  
 
 
 
Sources: Ozgul et al. [106] 
Figure 14. The major retinal isoform of MAK includes an alternative exon. 
 
Prevalence of the mutation was estimated to be 1.2% in a cohort of 1798 unrelated RP patients with 
mixed ethnicities. Interestingly, all individuals harbouring the mutation turned to have Jewish 
ancestry [107]. The clinical manifestation of MAK-Alu element insertion resembles that of an 
autosomal dominant form of RP due to mutations in the RP1 gene [108], which is intriguing 
considering that the two proteins co-localize in murine photoreceptors and that Rp1 is a target of 
Mak phosphorylation [105]. Prolonged survival of the central retina island with good acuity was 
observed as a typical feature of patients harbouring this mutation [108]. Nonsense and missense 
mutations affecting critical MAK residues have also been associated with arRP in other cohorts; 
overall the patients harbouring MAK mutations present a less rapid and severe disease course 
compared with other forms of arRP [106]. 
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1.5 Genomics technologies and disease gene identification strategies 
 
In 2001 the first draft of the complete sequence of the human genome was published [109], and few 
years later the human genome assembly was already of such a high quality to cover the 99% of the 
euchromatic regions [110]. The remaining megabases that failed to be assembled were mostly in 
repetitive regions, but could eventually contain genes.  
From 2007, personal genomes started to be sequenced and the 1000 genomes project was launched 
as an international collaboration to produce an extensive public catalog of human genetic variation 
by sequencing of thousands of genomes (www.1000genomes.org) [111].  
What was learned from sequencing personal genomes is that the human genome is extremely 
variable (3.5 million single nucleotide polymorphisms and 1000 large structural rearrangements on 
average/individual) and that a healthy individual can be a heterozygous carrier of about 50-100 
highly penetrant deleterious variants that can potentially represent a recessive carrier state for a 
Mendelian disease (data from the 1000 genomes project consortium 2010).  
Nowadays the identification of genes that are responsible for rare Mendelian disorders is becoming 
increasingly important, given the possibility to develop gene-based therapies that can restore the 
function of the mutated gene, especially for recessive diseases.  
Before the development of massively parallel sequencing, specific regions of interest of the DNA 
were either targeted by PCR or cloned into standard vectors and sequenced using a capillary-based, 
semi-automated implementation of the Sanger technique [112]. The high demand for low-cost 
sequencing has driven the development of high-throughput (NGS) technologies that parallelise the 
sequencing process, producing millions of reads (contiguous regions of DNA sequence) in one 
experiment [113]. 
NGS techniques have dramatically reduced the time and costs of conventional sequencing by 
simultaneously sequencing an increasing number of genes [114]. 
The crucial step of NGS is the production of a library of DNA fragments, which represents the 
template for further processing. Library preparation is accomplished by random fragmentation of 
the genomic DNA, followed by the ligation of special adapters. The fragmented DNA of interest is 
captured by targeted hybridization and then these DNA fragments are used to generate a library that 
is ready to be sequenced. For each variant to be analyzed the reads are reassembled using a known 
reference genome as a scaffold, resulting in many-fold coverage of the region of interest, or in the 
absence of a reference genome a de-novo assembly is performed.  
Whole exome and whole genome sequencing (WES and WGS) are currently the preferential 
approaches for disease gene identification in rare Mendelian diseases [115-116]. Exome sequencing 
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has successfully identified the causative mutations of several highly penetrant Mendelian diseases, 
it is about 5 fold less expensive than WGS and exon variations are the most readily interpreted at 
the moment. On the other side, it interrogates only 1% of the entire genome, suggesting that it could 
miss mutations of interests, including those in exons that are not captured, in non-exonic regulatory 
regions, or structural variants such as large deletions or duplications [117-118]. Another limitation 
of WES could be represented by the high average coverage that is required, because of the variable 
efficiency of the capturing method and of “allelic imbalance” when one allele is preferentially 
captured over the other [119]. 
It is becoming increasingly evident that variations in non-coding sequences of the genome or 
structural rearrangements may represent an important genetic component in Mendelian diseases. 
Whole-genome sequencing uncovers all genetic and genomic variations, including intronic and 
regulatory variants as well as large structural variations and copy number variants that can 
otherwise cause the disease. However, both costs and capacity required to perform whole genome 
sequencing are still prohibitive for daily use, considering that the function of much part of the 
genome is still largely unknown. 
By comparing results of exome sequencing of an individual with respect to genome sequencing of 
the same individual neither of the two techniques managed to cover all sequencing variants, 
suggesting that both approaches complement each other [120].  
The most powerful approach to solve the genetic causes of rare Mendelian diseases has been so far 
the sequencing of different members of the same family or of different individuals with the same 
phenotype [121-125].    
In addition, classical genetic approaches such as linkage analysis or homozygosity mapping, 
depending on the structure and inheritance pattern of the family, can help refining genomic regions 
of interest. 
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 Chapter 2 
 
 
 
CNOT3 is a modifier of PRPF31 mutations in retinitis pigmentosa 
with incomplete penetrance 
 
Published in PLOS Genetics (November 2012 | Volume 8 | Issue 11 | e1003040) 
 
The aim of this project was to look for genetic elements that could influence the penetrance of 
PRPF31-linked autosomal dominant retinitis pigmentosa, by which some obligate carriers of the 
disease allele do not show pathological symptoms. At least one of these elements was mapped by 
linkage analysis to chromosome 19q13.4, where PRPF31 lies as well. Isoalleles from this locus, 
inherited by the patients from the parent who does not carry the mutation, determine an increased 
level of wild-type PRPF31, which in turn prevents the clinical manifestation of the disease.  
 
The project was a collaboration with the group of Prof. S.S. Bhattacharya (Institute of 
Ophthalmology, University College London), who provided us lymphoblastoid cell lines derived 
from patients belonging to a large British family (RP856/AD5), which segregates a frameshift 
PRPF31 mutation.  
 
This study has led to the identification of the major regulator of the penetrance of PRPF31 
mutations, named CNOT3, and to the characterization of its mechanism of action in regulating 
PRPF31 expression. 
 
In this study I performed all the experiments except the sequencing of the polymorphic alleles, and I 
wrote the draft for the journal.  
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2.1 Additional experiments (unpublished results) 
 
Results, Part 1 and 2) After the publication of the paper we had access to two other families with 
PRPF31-linked adRP showing incomplete penetrance, thanks to which we were able to extend our 
analysis on CNOT3 expression and on the association of CNOT3 polymorphic alleles with the 
clinical manifestation of the disease. 
 
Results, Part 3) Together with the gene expression analysis in lymphoblastoid cells derived from 
patients belonging to the RP856/AD5 family (data published in PLOS Genetics) we performed also 
a microRNA analysis to see if there was an altered expression of microRNAs, which are known to 
be involved in the regulation of gene expression. 
 
Results, Part 4) We checked if the asymptomatic individuals of PRPF31-linked adRP families 
presented a higher expression not only of PRPF31 but also of other splicing factors. 
 
Results, Part 5 and 6) We tested in vitro if CNOT3 could affect the transcription of other splicing 
factors.  
 
Results, Part 7) As another subunit of the Ccr4-Not complex, called CNOT2, shares the same 
functional domain with CNOT3, we investigated if it could also modulate PRPF31 expression and 
whether its expression was altered in PRPF31-linked adRP families.   
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2.1.1 CNOT3 mRNA expression in two other families with PRPF31-linked 
autosomal dominant retinitis pigmentosa showing incomplete penetrance 
 
We measured CNOT3 expression levels in two North American adRP families that showed an 
incomplete penetrance phenotype linked to PRPF31-mutations.  
Family #1562 was originally described by Berson et al. [1] and later included in the large meta-
analysis that led to the identification of the major modifier of PRPF31 penetrance on chromosome 
19q13.4 [2]. The PRPF31 mutation, which causes the disease in the family, is deeply intronic 
(c.1374+654C>G) and represents the first PRPF31 pathological variant for which it has been 
proven that some residual wild-type transcript is derived from the mutated allele [3-4].  
Family #2474 harbors a 34 base pairs deletion in exon 9 of PRPF31, which leads to a premature 
stop at the amino acidic position 320 and to degradation of the transcript by nonsense-mediated 
mRNA decay [5].  
We had access to lymphoblastoid cell lines derived from two asymptomatic and one affected 
individual belonging to family #1562 and from one asymptomatic and one affected individual of 
family #2474.  
The inverse trend of expression between PRPF31 and CNOT3, which was observed in the 
RP856/AD5 family (PLOS Genetics paper, figure 1A and 1B), was confirmed in the two new 
families (Figure 1A).  
Cumulative expression of PRPF31 and CNOT3 in all families with different PRPF31 mutations is 
represented in Figure 1B. 
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Figure 1. CNOT3 expression with respect to that of PRPF31. A) Asymptomatic (AS) and affected (AF) 
individuals of families #1562 and #2474. PRPF31 and CNOT3 mRNA expression was normalized to the housekeeping 
gene GAPDH. Error bars refer to the standard deviation of the mean for 3 independent experiments for each group. B) 
Individuals of families RP856/AD5, #1562 and #2474 (in total 7 asymptomatic and 8 affected individuals). 
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2.1.2 CNOT3 polymorphic alleles in an additional pedigree of PRPF31-linked 
autosomal dominant retinitis pigmentosa showing incomplete penetrance 
 
CNOT3 rs4806718 alleles have been associated with the clinical manifestation of the disease in two 
unrelated pedigrees of PRPF31-linked adRP with incomplete penetrance (PLOS Genetics paper, 
figure 4). Association between the minor C allele with the affected status and the ancestral T allele 
with the asymptomatic status was moderately significant in the two families (p=0.04, PLOS 
Genetics paper, figure 4).  
Lately we had access to the DNA from 8 asymptomatic and 8 affected individuals belonging to 
family #1562. 
In 13 out of 16 individuals of the latter family there is a genotype-phenotype correlation for the 
rs4806718 alleles (Figure 2). 
Adding the data of this family to those of the other two families analyzed in the paper we obtain a 
highly significant association between the CNOT3 rs4806718 alleles and the clinical manifestation 
of the disease (p=0.002, by Fisher exact test).  
 
 
 
 
 
 
 
 
 
Figure 2. Analysis of CNOT3 rs4806718 alleles in the family #1562. Affected individuals are in black, 
while asymptomatic individuals are represented with a dot. M indicates the carriers of the PRPF31 mutation. 
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2.1.3 microRNA expression analysis in the asymptomatic and affected individuals 
of the RP856/AD5 family 
 
 
microRNAs (miRNAs) are small noncoding RNA molecules (≈ 22 nucleotides) that are broadly 
involved in the regulation of gene expression. By pairing with complementary mRNA sequences, 
they lead to translational repression or degradation of the target transcript, which finally results in 
gene silencing.  
Within the region on chromosome 19q13.4 that harbors the major modifier for PRPF31 penetrance 
there is the largest miRNA cluster of the human genome, known as the C19MC cluster, which 
contains 46 pre-miRNA genes.  
While we were testing the expression levels of all the genes that are present in the region on 
chromosome 19q13.4 in lymphoblastoid cells derived from patients belonging to the RP856/AD5 
family, we also performed miRNA expression analysis by using the nCounter human miRNA 
expression assay kit (Nanostring Technologies, Seattle, USA), which allows the contemporary 
digital detection of 654 human miRNAs in a single reaction without amplification.  
Only a minority of microRNAs that are detected by the kit (about 12%) are expressed in 
lymphoblastoid cells from the patients. Among these, we selected five miRNAs that show a 
statistically significant difference in expression between the asymptomatic and affected individuals 
of the R856/AD5 family (Figure 3).  
miR-518f belongs to the C19MC miRNA cluster on chromosome 19q13.4, but, according to three 
different prediction tools (miRanda, RNAhybrid, and TargetScan) is supposed to target neither 
PRPF31 nor CNOT3. However, we looked for a polymorphism within its sequence that could 
explain the different haplotypes observed on chromosome 19 by McGee et al. [2], but we could not 
find any polymorphism among the individuals of the R856/AD5 family.  
miR-193b is predicted to target both PRPF31 and CNOT3 by two different prediction tools 
(miRanda and RNAhybrid). Interestingly, in the miRNAMap database 
(http://mirnamap.mbc.nctu.edu.tw/), which reports experimentally verified miRNAs with their 
target genes, miR-193b expression positively correlates with that of CNOT3 and negatively 
correlates with that of PRPF31, which fits with the output of our experiment (Figure 3). 
The other three miRNAs that we selected (miR-191, miR-342-3p, and miR-425) are all predicted to 
target CNOT3 by the same prediction algorithm, which is interesting since in our experiment they 
show an opposite trend of expression with respect to that of CNOT3 (Figure 3).  
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Figure 3. Expression profiles of five miRNAs that show a statistically significant difference in 
expression between the asymptomatic (AS) and affected (AF) individuals of the RP856/AD5 family. 
Mann Whitney non-parametric statistical hypothesis test was used to compare the expression level of each miRNA 
between the two groups of individuals. One star indicates p<0.05, two stars indicate p<0.01.  
 
 
 
 
The data presented here are still preliminary and need to be validated with other techniques, such as 
Real-time PCR. Then, to confirm the possible effect of the five miRNAs on PRPF31 and CNOT3 
expression functional in vitro experiments should be performed.  
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2.1.4 Expression of other splicing factors in families with PRPF31-linked 
autosomal dominant retinitis pigmentosa showing incomplete penetrance 
 
 
Expression of PRPF3, PRPF8, BRR2, and PRPF6 was assessed in 7 asymptomatic and 8 affected 
individuals of families RP856/AD5, #1562, and #2474.  
Results show a tendency for all other components of the spliceosome we tested to be more highly 
expressed in the asymptomatic compared to the affected individuals (Figure 4). The result could be 
explained by a stoichiometric mechanism of the other spliceosome subunits to counteract the 
increased expression of PRPF31 in the asymptomatic individuals, although they are carriers of the 
mutation. 
 
 
 
 
 
 
 
 
Figure 4. Expression of other splicing factors between the asymptomatic (AS) and affected (AF) 
individuals of families RP856/AD5, #1562 and #2474. Mann Whitney non-parametric statistical hypothesis test 
was used to compare the expression of each gene among the two groups of individuals. p<0.05 is indicated by one star. 
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2.1.5 Effect of CNOT3 on the transcription of other splicing factors  
 
 
We wanted to investigate if CNOT3 could influence the transcription not only of PRPF31, but also 
of other proteins that make up the spliceosome, and in particular of those that have been associated 
with autosomal dominant forms of retinitis pigmentosa (PRPF3, PRPF8, BRR2, PRPF6).  
CNOT3 expression was inhibited in ARPE-19 cell lines, by using two different CNOT3-specific 
siRNA sequences. We observed a statistically significant effect with both CNOT3-specific siRNAs 
on the expression of PRPF31, PRPF6, and PRPF8 (Figure 5A), which was even confirmed at the 
protein level (Figure 5B). The effect on the expression of PRPF3 and BRR2 was less evident, since 
it was observed only by using one out of two CNOT3-specific siRNA sequences. 
This experiment is however not conclusive to establish if CNOT3 could directly affect the 
expression of the other spliceosome components; it may in fact be simply that the tendency of the 
other splicing factors to increase after CNOT3 suppression is only due to a stoichiometric 
mechanism in response to the increased expression level of PRPF31. 
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Figure 5. Effect of CNOT3 silencing on PRPF31, PRPF3, PRPF8, BRR2, and PRPF6 expression. A) 
mRNA expression. siRNA_1 and siRNA_2, different CNOT3-specific siRNA sequences; Control, treatment 
with transfection reagent with no siRNA; Mock, treatment with transfection reagent and scrambled siRNA. 
mRNA expression normalized to the housekeeping gene GAPDH. Error bars refer to the standard deviation 
of the mean for 3 independent experiments for each group. One-way ANOVA followed by Bonferroni’s 
multiple comparison tests was used to analyze the effect of CNOT3 silencing on the expression of the target 
genes. p<0.05 is indicated by one star, p<0.01 by 2 stars, and p<0.001 by 3 stars. B) Representative western 
blot of the effect of CNOT3 silencing on PRPF31, PRPF3, PRPF8, BRR2, and PRPF6 protein expression. 
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2.1.6 CNOT3 binding to the promoter of the other splicing factors 
 
In order to check if CNOT3 could directly affect the transcription of the other spliceosome 
components by binding to their predicted promoter sequences we performed chromatin 
immunoprecipitation (ChIP) in lymphoblastoid cells from three healthy individuals using an anti-
CNOT3 antibody and serum IgG as a negative control.  
Previously, a statistically significant enrichment of PRPF31 experimentally validated promoter 
sequences was found in the fraction that was immunoprecipitated with anti-CNOT3 antibody, 
compared to that immunoprecipitated with serum IgG (PLOS Genetics paper, Figure 3A and 3B). 
Predicted promoter sequences of the other splicing factors were retrieved from the Transcriptional 
Regulatory Element Database (http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=home). 
Our data show that CNOT3 seems to be able to bind weakly to the promoter sequences of other 
splicing factors (Figure 6), even if we only performed a qualitative estimation and not a 
quantification of the enrichment of the different promoter sequences in the fraction 
immunoprecipitated with the CNOT3 antibody compared to that immunoprecipitated with the 
serum IgG. 
Before jumping to conclusions we would still need to test many more negative control sequences, to 
make sure that the results we got are not due to a technical artifact.  
Moreover, promoter sequences of PRPF3, PRPF8, BRR2, PRPF6 should be tested with luciferase 
assay to determine if they are functionally active. 
 
 
 
 
 
 
 
 
Figure 6. CNOT3 binds to the promoter of PRPF31, PRPF3, PRPF8, BRR2, PRPF6 in lymphoblastoid 
cell lines. CNOT3 ChIP-PCRs on different target sequences. PTEN exon 8, DHFR 3’UTR, and GAPDH 
promoter sequences were used as negative controls. 
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2.1.7 CNOT2 expression in the RP856/AD5 family and effect of CNOT2 on 
PRPF31 transcription  
 
The Ccr4-Not complex consists of nine different subunits that control mRNA metabolism at 
different levels. Two of these subunits, CNOT3 and CNOT2, share a conserved protein motif, 
called the Not-Box domain, which has been shown to repress reporter gene activity upon promoter 
targeting [6]. We thought to test whether CNOT2 could also be a negative regulator of PRPF31 
expression and if it was differentially expressed between the asymptomatic and affected individuals 
of the RP856/AD5 family. Silencing of CNOT2 by three different CNOT2-specific siRNA 
sequences in HeLa cells shows no effect on PRPF31 mRNA expression (Figure 7A) and no 
alteration of CNOT2 expression levels was observed between the asymptomatic and affected 
individuals of the RP856/AD5 family (Figure 7B).  
 
A 
 
B 
               
 
Figure 7. A) Effect of CNOT2 silencing on PRPF31 mRNA expression. siRNA_1, siRNA_2, and siRNA_3, 
different CNOT2-specific siRNA sequences; Control, treatment with transfection reagent with no siRNA; 
Mock, treatment with transfection reagent and scrambled siRNA. mRNA expression normalized to the 
housekeeping gene GAPDH. Error bars refer to the standard deviation of the mean for 3 independent 
experiments for each group. p<0.001 is indicated by three stars. B) CNOT2 mRNA expression between the 
asymptomatic (AS) and affected (AF) individuals of the RP856/AD5 family. 
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 Chapter 3  
 
 
 
 
FAM161A mutations in patients with early-onset retinitis pigmentosa 
in North America 
 
 
The paper is ready to be submitted for publication. 
 
The aim of this project was to screen the recently identified FAM161A gene in a large cohort of 
North American individuals with autosomal recessive retinitis pigmentosa in order to identify novel 
mutations and better understand genotype-phenotype relationships.  
 
The project was a collaboration with Dr. Eliot L. Berson (The Berman-Gund Laboratory for the 
Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear, Boston, 
MA), who performed the clinical examination of patients.  
 
This project has led to the assessment of the prevalence of FAM161A mutations in North America, 
the ascertainment of genotype-phenotype correlations, and the identification of two alternative 
FAM161A transcripts in the human retina.  
 
In this study I performed all experiments except clinical examination of the patients and treatment 
of lymphoblastoid cell lines with cycloheximide, and I wrote the draft for the journal.  
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Objective: To assess FAM161A genotype-phenotype correlations in a cohort of North American 
patients.  
 
Methods: DNA from peripheral blood leukocytes was extracted from 273 unrelated patients with 
autosomal recessive retinitis pigmentosa (arRP) and 270 control individuals with no history of 
retinal degeneration. Mutational screening of coding regions and flanking intron boundaries was 
carried out by Sanger sequencing. Patients were clinically evaluated by ophthalmologic 
examination, including Goldmann visual field testing and computerized electroretinography 
(ERGs). Follow-up data were collected over 10 to 20 years. 
 
Results: Four patients carried the null-mutation p.T452Sfx3, which was previously reported as a 
founder DNA variant in the Israeli and Palestinian populations. ERG recordings displayed a 30 Hz 
flicker response in the range of 0.10 to 1.75 microvolts in all patients at first visit (age 12 to 23) and 
of 0.06 to 0.80 microvolts at their most recent examination (age 27-43). Visual fields areas to the V-
4e white light were all in the range of 80 deg2. 
 
Conclusions: Our data indicate that mutations in FAM161A are responsible for a small fraction of 
cases of arRP in North America (1.5%), similar to the prevalence detected in Germany and unlike 
the data from Israel and the Palestinian territories. All patients had ERG recordings compatible with 
early-onset arRP.  
 
Clinical Relevance: Patients with arRP so far studied with FAM161A mutations have early-onset 
retinal degeneration as monitored by full-field electroretinograms (ERGs). 
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Introduction 
Retinitis pigmentosa (RP) is a group of hereditary degenerative diseases of the retina associated 
with significant phenotypic and genotypic diversity. RP causes progressive loss of rod and cone 
photoreceptors function. Patients typically report loss of night vision in adolescence, loss of mid 
and far peripheral field in young adulthood, and loss of central vision in later life. Patients have 
elevated final dark adaptation thresholds and reduced and delayed full-field ERGs [1]. Studies of 
autopsy eyes have shown that the loss of visual function is due to degeneration of the photoreceptor 
cells [1]. 
At present, according to the RetNet database, over 60 genes have been associated with 
nonsyndromic RP, which account for 50-60% of patients with this condition [2-3]. Mutations in 
FAM161A have been found to represent the cause of RP28-associated autosomal recessive RP in the 
initial Indian family in which the RP28 locus was mapped, as well as in a cohort of German patients 
[4]. Frequent nonsense mutations in FAM161A were also identified in patients from Israel and the 
Palestinian territories [5].  
FAM161A is well-conserved among vertebrates and, despite having multiple splicing variants, only 
two of them produce stable mRNA transcripts. The main splicing variant contains six exons and 
encodes for a protein of 76 kDa, while the second variant contains a supplementary 168 bp in-frame 
exon between exons 3 and 4. The protein is mainly expressed in the retina and in the testis and 
localizes in photoreceptor cells during mouse retinal development [4-5].  
Patients with FAM161A mutations have been reported to have symptoms ranging from an atypically 
late-onset form of RP, detected in a German cohort, to an early-onset manifestation of the disease, 
as observed in Israeli and Palestinian individuals. Unexpectedly, despite these clinical differences, 
patients so far reported carry the same class of mutations, leading to the loss-of-function of the 
encoded protein. 
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Here we report results of our mutational screening of FAM161A in a cohort of patients with 
autosomal recessive RP from North America, with the aim of assessing the mutation spectrum in 
this population and to increase our knowledge of the relationship between genotype and phenotype.  
Methods 
Patients and controls  
This research was carried out in accordance with the tenets of the Declaration of Helsinki and was 
approved by the Institutional Review Boards of the University of Lausanne and of Harvard Medical 
School and the Massachusetts Eye and Ear, where the blood was collected and the patients were 
followed. Written informed consent was obtained from patients who participated in this study 
before they donated 10-30 ml of their blood for research. 
DNA from peripheral blood leukocytes was extracted from 273 unrelated patients with arRP. 
Controls included 95 individuals with no history of retinal degeneration, and 80 subjects with 
normal ERGs. In addition, DNA samples from 95 ethnically-matched healthy individuals were 
purchased from the Coriell Institute Repository. For some individuals the quantity of DNA was 
insufficient to perform direct mutation screening and therefore a whole-genome amplification kit 
(REPLI-g Mini Kit, Qiagen) was used. 
 
Mutation screening 
Primer pairs for individual exons and relevant intron boundaries were designed using the CLC bio 
genomics workbench (see Table 1 Appendix). Amplifications by PCR were performed in 25 µl 
reactions containing 20 ng genomic DNA, 1x GoTaq buffer, 1.2 mM MgCl2, 0.1 mM dNTPs, 0.4 
µM of each primer, and 0.01 U/µl of GoTaq polymerase (Promega). Amplification conditions were: 
an initial step at 95°C for 2 minutes, 35 cycles of denaturation at 94°C for 30 seconds, annealing 
according to primers’ melting temperature for 30 seconds, and extension at 72°C for 1 minute. 
Before the end of the reaction, a final extension step at 72°C for 5 minutes was performed. 
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Sequencing reactions were carried out by Sanger sequencing, after purification of PCR products 
(ExoSAP-IT, USB), by using 1 µl of 3.3 µM sequencing primer (see Table 2 Appendix) and 0.5 µl 
of BigDye Terminator v1.1 (Applied Biosystems). The products of these sequencing reactions were 
run on an ABI-3130XLS sequencer (Applied Biosystems).  
 
Cell culture and drug treatment 
The Epstein-Barr virus immortalized lymphoblastoid cell lines used in this study were derived from 
two affected patients (003-161 and her sibling 012-001), and were cultured as previously described 
[6]. Normal control cell lines were purchased from the Coriell Cell Repository. Treatment of cells 
with cycloheximide was performed as previously reported [7].  
FAM161A primers for cDNA amplification were 5’-ggaagaaacgaaaagaatgg-3’ and 5’–
ttctcgttggtattctctcatcc-3’, yielding a 1,115 bp product. 18S ribosomal RNA was used as a 
housekeeping gene for this analysis, and primers for its cDNA amplification were 5’-
cggctaccacatccaaggaa-3’ and 5’–gctggaattaccgcggct-3’ (resulting in a 187 bp product). 
 
RLM- RACE  
To perform RLM-RACE we used the FirstChoice RLM-RACE kit (Invitrogen), following the 
manufacturer’s instruction. One microgram of total RNA from human retina (Clontech) was used to 
perform 3’UTR RLM-RACE, and ten micrograms of total RNA from human retina (Clontech) and 
from retinoblastoma cell line Y79 were used for 5’UTR RLM-RACE.  
 
Results 
We screened FAM161A in 273 unrelated patients with arRP from North America, and in 270 
ethnically matched healthy individuals. In three of these patients we identified the null mutation 
p.Thr452SerfsX3 (Table 1), which was previously reported as a founder mutation in an Israeli 
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Jewish population [5]. The same mutation was subsequently identified in one of the index patient’s 
relatives (012-001, sister of 003-161). All four patients carrying p.Thr452SerfsX3 were 
homozygotes for this mutation.  
Mutation p.Thr452SerfsX3 is predicted to produce a transcript that could be a target for nonsense 
mediated mRNA decay (NMD) and therefore result in no protein product. In order to test this 
hypothesis, we treated lymphoblastoid cell lines derived from the two siblings carrying this change 
(003-161 and 012-001) with the chemical NMD inhibitor cycloheximide. Upon supplementation of 
this inhibitor, mRNA degradation was blocked in both cell lines, confirming that p.Thr452SerfsX3 
is a null allele (Figure 1).  
In our cohort we also found a few other rare variants, likely having no pathological relevance 
(Table 2). Variant p.Q385E (rs139266382, MAF<0.01) was previously identified as heterozygous 
change in arRP patients and in healthy controls with a frequency of 2/400 alleles [4]. In our 
screening, we identified it in one patient and in 2 individuals from our control cohort. Variant 
p.H464R (rs201315315, MAF<0.01) was found in homozygous state in two arRP patients and in no 
healthy controls. The remaining variants were neither annotated in the dbSNP database nor were 
found in the control cohort. However, they all involved amino acid residues that are not 
evolutionary conserved and were predicted to result in benign changes by in silico analyses.  
Variant p.L378R was previously identified in the German cohort of patients who were screened for 
FAM161A mutations and was not present in 400 control alleles, thus was classified as a rare variant 
with uncertain pathogenicity. It involves a highly conserved residue and is predicted to be 
deleterious by 3 out of 4 prediction programs (Polyphen, SIFT, MutPred, and PMut). Recently, it 
has been annotated in the dbSNP database (build 135/137, rs187695569), with a minor allele 
frequency (MAF) of 0.4%. We identified it in a heterozygous state in 5 out of 273 arRP patients and 
in 2 healthy individuals from the Coriell control cohort.  
To test the hypothesis that heterozygous changes detected in our cohort of patients could in fact 
represent unrecognized mutations, we ascertain whether there were other non-annotated FAM161A 
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exons in retina. We therefore performed 5’ and 3’ RLM-RACE PCR using pooled retinal RNA 
from different donors, and identified two additional transcripts with an alternative 5’UTR in intron 
1, whose sequence corresponds to the annotated exon 2 of FAM161A-003 isoform. In these 
transcripts the translation-initiation codon lies on the canonical exon 2 (Figure 2). These transcripts 
were expressed in the retina at lower levels compared to the major isoforms. Interestingly, one of 
them completely skipped the highly-conserved exon 3, where most FAM161A mutations have been 
so far reported. We therefore screened this alternative 5’UTR sequence in the patients, but we did 
not find any possible-pathological variant.  
 
Discussion 
FAM161A mutations were recently identified in patients with recessive retinitis pigmentosa [4-5]. 
All reported mutations lead to loss-of-function of the encoded protein, but clinical manifestations of 
the disease may vary widely depending on the mutation. Prevalence of FAM161A-linked recessive 
RP is also different in individuals from different ethnicities, being in the German population 
comparable to the prevalence of most arRP genes [4], while, in the Israeli and Palestinian 
populations, FAM161A is the most frequently mutated gene in patients with arRP [5]. 
We found 4 patients with arRP and FAM161A mutations out of the 273 whom were screened, 
indicating that this is a relatively rare cause of RP in North America. Interestingly, one variant that 
had previously been reported as a founder mutation in the Israeli and Palestinian population 
(p.T452Sfx3) [5] is the most frequent mutation in patients from our cohort, and all but one of them 
reported Jewish ancestry.  
Furthermore, from our study it emerged that there are many rare variants in FAM161A, which are 
reported in dbSNP with a minor allele frequency of less than 1%, that are frequently found in 
patients but not in controls, whose functional meaning is uncertain.  
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Patients with FAM161A mutations clinically showed early onset RP with relatively good acuity and 
very reduced ERGs (Table 3). Follow up examinations 10-20 years after the initial visit showed 
that all retained good acuity in at least one eye, 3 of 4 showed further loss of visual field, and 1 
showed further decline in the ERG (Table 3). A floor effect may have occurred in those with less 
than or equal to 0.34 µV at their initial visit that could simulate stabilization. Visual field areas to 
the V-4e white test light were all in the range of 80deg2. The long-term course of arRP associated 
with FAM161A mutations remains to be defined.   
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Table 1 Appendix.   Primers for polymerase chain reaction amplification of FAM161A exons 
 
Targeted 
Exon Sense primer Antisense primer 
Annealing 
temperature 
(°C) 
Amplification 
product  
(bp) 
Exon 1 AGTGGATTTTGCGTGACTTTTG AATAACGAAACACACCTGACAGAAC 59 728 
Exon 2 CTCCCTCTCGTTCTTAAAATATCAC TGGGTGGGTCAGAAAGAAAAGAC 59 668 
Exon 3 
(I) 
 
GTAAAATGAAGGAGTCAAAGTGGA 
 
CACCTAACCTTGTGTTTACACTTC 
 
58 1359 
Exon 3 
(II) 
 
GATTTAAAGCCAGACCCATTCCT 
 
CCCAGCCAGGTAAAACTAGAAATC 56 768 
Exon 3a 
 
ATTCTGATTGGCTTAAAGTGG 
 
 
TGGCTTTGAGGGAGATAGTTTC 
 
62 807 
Exon 4 
 
GAGAATTAACCGGTATAGAAGAGGA 
 
ATGATGAAGCCAACACAAACAACA 56 437 
Exon 5 
 
GGAGTGTAATTGTTGGTCATAGGGT 
 
 
AAACGCTATAAAAGTGCCCATTG 
 
53.5 969 
Exon 6 ATACTTGCAGAGGGTTTGTTTAC AACCACCAAAGACCAATACTTCTC 59 591 
 
bp: base pair 
 
 
 
 
Table 2 Appendix.      Primers for Sanger sequencing of FAM161A exons 
 
Targeted 
Exon Sequencing primer 
Exon 1 
 
GTAGGGACTATGTGCACAGG 
 
Exon 2 AAGCAGCATTTTGGATCAGTG 
Exon 3 
(I) 
 
TACAAGGCAGAGGAGATGA 
 
Exon 3 
(II) 
 
CAACATAAACTCCACAGAGC 
 
Exon 3a 
 
ATTCTGATTGGCTTAAAGTGG 
 
Exon 4 CTTTGTACAAGTTGATAAGT 
Exon 5 
 
CTCGTCTAAAAAGGTTTGTC 
 
Exon 6 TAAACACAAATGCGGCTGCT 
a 
a 
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Table 1.      Pathogenic variants detected 
 
 
Table 2.      Possible non-pathogenic variants identified in this study 
 
 
 
 
 
 
 
 
Patient 
ID 
Ethnic 
origin 
Gene 
exon 
Nucleotide 
change 
Predicted 
effect Polyphen SIFT MutPred PMut 
Controls 
frequency 
(alleles) 
Reference 
of the 
variation 
003-161 Jewish (European) 3 c.1355_6delCA 
p.Thr452SerfsX3/ 
p.Thr452SerfsX3 - - - - 0/540 
Bandah-
Rozenfeld 
et al. 
003-257 Jewish (Moroccan) 3 c.1355_6delCA 
p.Thr452SerfsX3/ 
p.Thr452SerfsX3 - - - - 0/540 
Bandah-
Rozenfeld 
et al. 
121-385 Caucasian 3 c.1355_6delCA p.Thr452SerfsX3/ p.Thr452SerfsX3 - - - - 0/540 
Bandah-
Rozenfeld 
et al. 
012-001 Jewish (European) 3 c.1355_6delCA 
p.Thr452SerfsX3/ 
p.Thr452SerfsX3 - - - - 0/540 
Bandah-
Rozenfeld 
et al. 
           
Gene 
exon 
Nucleotide 
change 
Predicted 
effect 
Polyphen  SIFT MutPred PMut 
NNSPLICE 
0.9 
Controls 
frequency 
(alleles) 
Reference 
of the 
variation 
3 c.1133 T>G p.Leu378Arg/+ 
probably 
damaging 
tolerated disrupted pathological 
 
2/540 
Langmann 
et al. 
3 c.1113 C>G p.Asp371Glu/+ benign tolerated benign neutral  0/540 This study 
3 c.1153 C>G p.Gln385Glu/+ 
probably 
damaging 
tolerated benign neutral 
 
2/540 
Langmann 
et al. 
3 c.1391 A>G 
p.His464Arg/ 
p.His464Arg 
benign tolerated benign pathological 
 
0/540 This study 
intronic 
c.362+89 
C>T 
- - - - - 
acceptor site 
score 
increased 
NA This study 
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Table 3.    Clinical summary of patients with FAM161A mutations associated with retinitis 
pigmentosa 
 
 
 
First Visit 
 
# BGLid Age Sex VA OD 
VA 
OS 
ERG 
OD 
ERG 
OS 
Visual 
Field 
OD 
Visual 
Field 
OS 
DA Lens OD 
Lens 
OS 
Macula 
OD 
Macula 
OS 
Periphery 
OD 
Periphery 
OS 
1 003-161 12 F 20/40 20/30 0.10 0.10 1174 2016 3.0 -­‐ -­‐ -­‐ -­‐ + + 
2 003-257 21 F 20/50 20/40 0.10 0.10 108 76 3.0 -­‐ + -­‐ -­‐ + + 
3 121-385 23 M 20/20 20/20 0.24 0.6 2060 1795 3.0 + + -­‐ -­‐ + + 
4 012-001 12 F 20/40 20/40 0.10 0.10 78 78 3.0 + + -­‐ -­‐ + + 
 
 
 
Last Visit 
 
 
 
Visual Acuity: best corrected Snellen visual acuity 
Visual Field: Goldmann total field area to V-4e white test light (lower norm = 11,399 degrees squared) 
DA (dark adaptation): final threshold in log units above normal after 45 minutes of dark adaptation. 
ERG: full field ERG amplitude in microvolts to white light 30HZ white light (lower norm =50 microvolts) 
Lens: clear lens -; central posterior subcapsular cataract +; PP: pseudophakia 
Macula: within normal limits -;granular +; AS: atrophic scar 
Periphery: bone spicule or clumped pigment in one or more quadrants: +present, -absent 
NA denotes data not available 
# BGLid Age Sex VA OD 
VA 
OS 
ERG 
OD 
ERG 
OS 
Visual 
Field 
OD 
Visual 
Field 
OS 
DA Lens OD 
Lens 
OS 
Macula 
OD 
Macula 
OS 
Periphery 
OD 
Periphery 
OS 
1 003-161 27 F 20/30 20/25 0.17 0.24 123 118 NA -­‐ -­‐ -­‐ -­‐ + + 
2 003-257 38 F HM 20/60 0.06 0.10 NA NA 4.0 + + AS + + + 
3 121-385 43 M 20/20 20/30 0.22 0.32 69 65 4.0 PP PP + + + + 
4 012-001 30 F 20/30 20/30 NA NA 43 73 NA + + -­‐ -­‐ + + 
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Figure 1.  Mutation p.T452SfsX3 produces a transcript with a premature stop codon that is a 
target for NMD degradation. For each sample the first lane corresponds to the cells treated with 
cycloeximide, while the second lane corresponds to the untreated cell line. CTR: RT-PCR from a 
control individual. 18S: RT-PCR loading control (18S rRNA). 
 
 
   
 
 
 
 
Figure 2.  An alternative 5’UTR is present in intron 1 and is part of two newly-discovered 
splicing isoforms. In the top panel, the canonical form, as reference. 
 
 
 
 
 
 
 
 
 
FAM161A 
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003-161 012-001 CTR 
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 Chapter 4 
 
 
 
 
A 353-bp Alu insertion in MAK is a prevalent cause of 
recessive retinitis pigmentosa in North American Jewish patients 
 
 
For coherence with the rest of the thesis the following results are presented in the form of a 
scientific article even if additional experiments are necessary before submission to a journal.   
 
The project aimed at: (1) assessing the prevalence of a recently-reported 353-bp Alu insertion in 
exon nine of the male germ cell-associated kinase gene (MAK) in a cohort of North American 
autosomal recessive retinitis pigmentosa (arRP) patients with Jewish ancestry, compared with a 
cohort of arRP patients with mixed ethnicity; (2) ascertaining whether the insertion could be a 
founder mutation in the Jewish population; (3) identifying an Ashkenazi Jewish haplogroup in all 
patients harbouring the mutation. 
 
The project is a collaboration with Dr. Eliot L. Berson (The Berman-Gund Laboratory for the Study 
of Retinal Degenerations, Harvard Medical School, Massachussetts Eye and Ear, Boston, MA), who 
performed the clinical examination of patients.  
 
So far the project has led to the ascertainment of the prevalence of the mutation in North American 
arRP patients with Jewish family history and with mixed ethnicity and to the identification of five 
homozygous SNPs around the mutation, which define a founder RP-associated haplotype in the 
Jewish population.  
 
In this study I performed all experiments expect the clinical examination of patients.  
Hanna Koskiniemi, a postdoctoral fellow in the laboratory, has largely contributed to the haplotype 
analysis.  
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Objective: 1) To ascertain the prevalence of a previously reported 353-bp Alu insertion in exon 
nine of male germ cell-associated kinase (MAK) in a cohort of North American autosomal recessive 
retinitis pigmentosa (arRP) patients with Jewish ancestry, compared with a cohort of arRP patients 
with mixed ethnicity, and 2) to assess that the insertion could be a founder mutation in the Jewish 
population. 
 
Methods: Thirty-five unrelated North American individuals were included in the cohort of arRP 
patients with Jewish ancestry and 241 North American arRP patients with mixed ethnicity were 
selected for the cohort of mostly Caucasian individuals. Patients were clinically evaluated by 
ophthalmologic examination, including Goldmann visual field testing and computerized 
electroretinography (ERGs). Mutational screening was performed by agarose gel analysis of PCR 
amplicons, followed by Sanger sequencing. Haplotype analysis was accomplished by sequencing 
eight polymorphic markers around the mutation.  
 
Results: The Alu insertion in exon nine of MAK was identified in 9 out of 35 (26%) arRP patients 
with Jewish ancestry and in 5 out of 241 (2.1%) arRP patients with mixed ethnicity. The latter 
positive individuals reported all East European origin, which could be compatible with Ashkenazi 
Jewish ancestry. A founder haplotype was identified in all patients carrying the mutation. 
 
Conclusions: A 353-bp Alu insertion in MAK is a prevalent cause of arRP in North American 
Jewish patients and represents a founder mutation among Jews.  
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Introduction 
The male germ cell-associated kinase (MAK) is a serine/threonine protein kinase encoded in 
humans by the gene MAK, which maps on the short arm of chromosome 6.  
It is a highly-conserved enzyme, the expression of which is limited to testis [1] and retina [2]. 
Four alternative MAK isoforms are present in humans; the longer isoform, containing an alternative 
75-bp exon between exons 11 and 12, has a photoreceptor-specific expression both in mice and in 
humans [3-5].  
In mice, Mak regulates photoreceptor ciliary length and is crucial for photoreceptor long-term 
survival, since Mak-/- mice develop progressive retinal degeneration [3].  
Recently, mutations in MAK have been identified as a cause of autosomal recessive retinitis 
pigmentosa (arRP) [4-5]. A homozygous 353-bp Alu insertion in exon 9 of MAK has been reported 
in an isolate arRP patient with Jewish ancestry [5]. The mutation results in the insertion of 31 
incorrect amino acids followed by a premature termination codon; in retinal cells derived from 
patient’s fibroblasts the mutation prevents the expression of the photoreceptor-specific isoform [5]. 
Screening of the Alu insertion in a cohort of 1798 unrelated arRP patients with mixed ethnicity 
identified 20 probands homozygous for the mutation (1.2%); interestingly, all carriers of the 
mutation reported Jewish ancestry [5].  
Clinical manifestation in individuals harbouring the Alu insertion resembles the autosomal 
dominant form of RP linked to RP1 mutations [6]. This is an intriguing finding considering that in 
murine photoreceptors Mak and RP1 have been shown to co-localize and RP1 is a target of Mak 
phosphorylation [3]. Prolonged survival of the central retina island and good visual acuity are 
typical features in patients with the Alu insertion in MAK [6]. 
Nonsense and missense mutations affecting critical residues of the protein have been reported 
among Caucasians; patients with MAK mutations show an overall less rapid and severe disease 
course compared with other recessive forms of RP [4]. 
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Retinitis pigmentosa is a heterogeneous Mendelian disease whose recessive way of inheritance is 
caused by mutations in more than 30 genes and loci (according to RetNet database, 
https://sph.uth.edu/retnet/), most of which account for a small percentage of cases.  
Based on the estimated carrier frequency in the Jewish population [6] the Alu insertion in MAK is 
expected to be responsible of about one third of all RP cases among Jews.  
In our study we ascertained the prevalence of the Alu insertion in MAK in a cohort of North 
American patients with arRP and of Jewish ancestry, compared with a cohort of patients of mixed 
ethnicity. Furthermore, we proved that the insertion is a founder mutation in the Jewish population.  
 
Methods 
Patients  
This research was carried out in accordance with the tenets of the Declaration of Helsinki and was 
approved by the Institutional Review Boards of the University of Lausanne and of Harvard Medical 
School and the Massachusetts Eye and Ear Infirmary, where the blood was collected and the 
patients were followed. Written informed consent was obtained from patients who participated in 
the study before they donated 10-30 ml of their blood for research. 
DNA from peripheral blood leukocytes was extracted from 35 unrelated North American arRP 
patients with Jewish ancestry, and from 241 North American arRP patients with mixed ethnicity.  
Patients were clinically evaluated with an ophtalmologic examination, including Goldmann visual 
field testing and computerized electroretinography (ERGs). 
 
Genetic analyses 
Mutational screening was performed by agarose gel analysis of PCR amplicons, followed by Sanger 
sequencing. Primer sequences to amplify the Alu insertion in exon nine of MAK were designed 
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using Primer3 software. Forward primer: 5’-TACCGCCCATTTTTGTTCAT-3’ (intron 8/9); Reverse 
primer: 5’-ACTGAGAACTGTTACTGTGAG-3’ (intron 9/10).  
PCR amplification was performed in a 25 µl reaction containing 20 ng genomic DNA, 1x GoTaq 
buffer, 1.2 mM MgCl2, 0.1 mM dNTPs, 0.4 µM of each primer, and 0.01 U/µl of GoTaq polymerase 
(Promega). Amplification conditions were: an initial step at 95°C for 2 minutes, followed by 35 
cycles of denaturation at 94°C for 30 seconds, annealing at 56°C for 30 seconds, and extension at 
72°C for 1 minute. Before the end of the reaction, a final extension step at 72°C for 5 minutes was 
performed. After purification of the PCR product (ExoSAP-IT, USB), the sequencing reaction was 
carried out by Sanger sequencing using 3.2 µM of sequencing primer (5’-
CACTGAGTCATAAAAGTGGT-3’) and 0.5 µl of BigDye Terminator v1.1 (Applied Biosystems). 
The sequencing product was then run on an ABI-3130 XLS sequencer (Applied Biosystems).  
Haplotype analysis was accomplished by sequencing eight polymorphic markers around the 
mutation, using PCR conditions reported above and primer pairs listed in Table S1.  
 
Results 
We identified 14 individuals harbouring the Alu insertion in exon nine of MAK in a homozygous 
state (Figure 1). Of these, 9 belonged to the cohort of arRP patients with Jewish ancestry, which 
corresponds to a prevalence of 26% in the Jewish population, and 5 to the cohort of arRP patients 
with mixed ethnicity (prevalence of 2.1%). However, the latter positive individuals reported all East 
European origin, which could be compatible with Ashkenazi Jewish ancestry.   
The mean age of onset of the disease in patients with the mutation is 45 years (n=14; 29-64 years at 
first visit), indicative of a late-onset form of arRP. In agreement with what was previously observed 
by Stone et al. [6], patients carrying the Alu insertion in MAK have rather good visual acuity, which 
suggests a prolonged survival of the central retina (Table 1). 
 84 
Interestingly, three individuals from our cohort present ocular manifestations that differ from the 
average of all other patients, being more severe in patient 121-847, who shows an important 
reduction of the visual field and almost unrecordable cone responses, but milder in patients 003-213 
and 003-033, who have a more preserved photoreceptor function (Table 1). An assumption could 
be that these patients harbour additional variants that, added to the effect of the mutation, are able to 
modulate the phenotype. 
By sequencing eight polymorphic markers in a region of about 230 kb around the mutation we 
identified, in all 14 patients, five homozygous SNPs, which define a founder RP-associated 
haplotype in the Jewish population (Table 2). The same haplotype was not found in 9 arRP patients 
with Jewish ancestry not carrying the mutation.  
 
Discussion 
In the United States there is the largest Jewish community outside of Israel in the world. The 
majority of Jews who live in the US are Ashkenazi Jews (AJ), a population that, around the 4th 
century, migrated from the Middle East to Europe. At the end of the 19th century and beginning of 
the 20th century they mostly moved from Central and Eastern Europe to the United States and to 
Israel.  
Although consanguineous marriages are not common in Ashkenazis compared to other Jewish 
populations, there is still a high rate of intra-community marriages, therefore disease-causing 
mutations in recessive disorders affecting AJ are expected to be found in a homozygous state [7].  
There is a growing list of genes that have been shown to be responsible for a high percentage of 
cases of recessive retinal degenerations in the AJ population (i.e. CLRN1 [8], PCDH15 [9], 
and DHDDS [10-11]).  
The 353-bp Alu insertion in exon 9 of MAK has been predicted to be a prevalent cause of recessive 
retinitis pigmentosa in the AJ population, based on its high carrier frequency among individuals 
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with AJ ancestry [6]. In our cohort of North American arRP patients with Jewish family history we 
found a prevalence of the mutation of 26%, slightly below the estimation of 1:3 in Ashkenazi Jews 
[6].  
RP caused by the Alu insertion in MAK, compared to other forms of arRP, shows a later onset and 
less severe symptoms, such as better visual acuity and prolonged survival of the central retina. 
Haplotype analysis showed a shared homozygous region of five polymorphic markers among all 
individuals carrying the mutation, suggesting that the Alu insertion is a founder mutation in the 
Jewish population and that all individuals with mixed ethnicity who were found to harbour the 
mutation may probably have Jewish ancestry as well. 
We still need to demonstrate that patients carrying the Alu insertion in MAK are indeed Ashkenazi 
Jews; one approach could be to sequence the entire mitochondrial genome, which contains 
polymorphic markers that define the four major Ashkenazi Jewish haplogroups. 
In conclusion, because of its high prevalence in the Jewish population, MAK should definitely be 
included in Jewish carrier screening panels with the aim of reducing the incidence of arRP in this 
population.  
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Figure 1. A representative agarose gel of PCR amplicons, on which two homozygous carriers of the 
mutation (circled in red). 
 
 
 
 
 
 
Table 2. Polymorphic markers used for haplotype analysis. In red the SNP closest to the 
mutation. The shared haplotype highlighted in blue. 
 
 
 
 
 
 
 
 
1kb - 
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SNP ID Variant MAF Forward primer Reverse primer 
rs111468923 C>T 0.02 TTGCCTAGCAGGAATTGCCA GCAGAGGGGAGACTACAGGA 
rs1045911 A>C 0.16 CACCGTCCCCATTCTCTGAC TAAGCCTTTGCCTCAGGAGC 
rs545019 G>A 0.34 CCTGACCTCAGGTGATCCAT CTCTGGTTCTTCCTGCCTTG 
rs116734564 G>C 0.01 CTCCCGAAGTGCTGGGATTA GAATGTGCTAGATCTTGTCTG 
rs518954 (*) T>G 0.25 TACCGCCCATTTTTGTTCAT ACTGAGAACTGTTACTGTGAG 
rs7766477 A>C 0.26 ATCTCCCTGCACCCAACA CCCCATTCTCAAGGAGCGTT 
rs9357021 A>G 0.21 ACAGAACCTCAGAGTGTATATAGTAGT TCATAAAACCCCCAGTGTCCAAT 
rs12215477 A>G 0.21 TCCCTCTTTTCCTATGGTTGTGG CCTGGTAACTGAAGACTAAGGGA 	  
 
Table S1.  Primers used for haplotype analysis. (*) SNP closest to the mutation; to sequence it we 
used an additional sequencing primer (5’-ACAGGTGCACACCACCACAC-3’ ). MAF, minor allele 
frequency.
 89 
 
 
MGID Ancestry Age (y) Sex 
Visual 
Acuity 
OD 
Visual 
Acuity 
OS 
Visual 
Field  
OD 
Visual 
Field  
OS 
DA 
0.5HZ 
ERG 
OD 
0.5HZ 
ERG 
OS 
30HZ 
ERG 
OD 
30HZ 
ERG 
OS 
Lens  
OD 
Lens  
OS 
Macula 
OD 
Macula 
OS 
Periphery 
OD 
Periphery  
OS 
003-
321 
Hungarian/ 
Austrian/ 
Black 
Russian 
29 F 20/30 20/25 5401 5877 2.0 5.80 2.10 0.53 0.76 + + - - + + 
121-
216 Jewish 31 M 20/30 20/30 2497 6684 NA 1.50 3.70 0.41 0.94 + + + + + + 
121-
410 
Russian/ 
Polish/ 
English 
31 F 20/20 20/20 5898 6102 1.0 7.00 6.00 0.98 0.87 - - - - + + 
003-
370 
Polish/ 
Israeli 35 M 20/80 20/70 2593 1920 3.5 NA NA 0.40 0.47 + + + + + + 
121-
122 Jewish 42 M 20/25 20/30 9381 9140 NA 1.40 1.00 2.11 0.88 + + + + + + 
003-
213 
Hungarian/ 
Russian 42 F 20/20 20/25 11835 10735 2.5 22.00 19.00 7.31 8.43 - - - - + + 
003-
033 Jewish 43 M 20/20 20/20 6566 7412 NA 28.00 25.50 13.99 12.76 + + - - + + 
121-
184 Jewish 44 M 20/30 20/20 679 1447 NA 2.30 3.20 0.41 0.51 + + - - + + 
121-
147 Jewish 46 M 20/30 20/40 2163 3354 NA NA NA 0.20 0.13 + + + + + + 
121-
265 Jewish 47 M 20/25 20/25 7694 3290 NA 0.70 1.60 0.37 0.51 + - + + + + 
121-
470 Jewish 54 M 20/40 20/30 5934 4811 3.0 4.20 NA 1.75 0.63 + + - - + + 
121-
283 Jewish 55 M 20/80 20/80 1665 1415 4.5 NA NA 0.20 0.36 + + + + + + 
121-
847 Jewish 63 M 20/60 20/40 264 253 3.0 NA NA 0.09 0.08 Aphakia Aphakia + + + + 
003-
287 
Russian/ 
Romanian 64 F 20/30 20/40 277 255 4.0 NA NA 0.19 0.19 + + + + + + 
 
Table 1. Clinical summary of first visit with all tests of 14 patients with the Alu insertion in 
MAK. Visual Acuity: best corrected Snellen visual acuity; Visual Field: Goldmann total field area 
to V-4e white test light (lower norm = 11,399 degrees squared); DA (dark adaptation): final 
threshold in log units above normal after 45 minutes of dark adaptation; ERG: full field ERG 
amplitude in microvolts to white light single 0.5HZ flash (lower norm =350), 30HZ white light 
(lower norm =50); Lens: clear lens -; central posterior subcapsular cataract +; Macula: within 
normal limits -; granular +; Periphery: bone spicule or clumped pigment in one or more quadrants: 
+present, -absent; NA  denotes data not available.
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 Chapter 5 
 
 
 
 
Genome-wide sequencing to identify disease-causing mutations 
in patients with recessive retinitis pigmentosa 
 
 
For coherence with the rest of the thesis this part will be presented in the form of a scientific paper 
even if additional experiments are needed to conclude the project. 
 
The purpose of this study was to apply whole genome sequencing to identify disease-causing 
mutations in unrelated patients with recessive retinitis pigmentosa. 
 
The project is in collaboration with Dr. Eliot L. Berson (The Berman-Gund Laboratory for the 
Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear, Boston, MA) 
and Dr. Koji M. Nishiguchi (Department of Ophthalmology, Nagoya University School of 
Medicine, Nagoya, Japan), who provided us DNA of the patients and performed the clinical 
examinations.  
 
From the beginning this project was a close collaboration with Hanna Koskiniemi, a postdoctoral 
fellow in the laboratory, with whom we equally contributed to the results presented here. 
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Objective: To identify disease-causing mutations in unrelated individuals with recessive retinitis 
pigmentosa for diagnostic purposes. 
 
Methods: DNA from twelve Japanese and four North American unrelated individuals with 
recessive retinitis pigmentosa were subjected to whole genome sequencing, which was performed at 
Complete Genomics Inc. (Mountain View, CA, USA). We focused on the analysis of variants in 
157 genes, which have been reported to be associated with inherited retinal degenerations. 
 
Results: We identified causative mutations in 5 Japanese and in 2 North American individuals, 
accounting for about 44% of our cohort. 
 
Conclusions: Whole genome sequencing allowed the identification of disease-causing mutations in 
unrelated individuals with a genetically heterogeneous Mendelian disorder, supporting the notion 
that such strategy can be successfully used in molecular diagnostic of RP. 
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Introduction 
Autosomal recessive retinitis pigmentosa (arRP) starts early, usually during the first decade of life, 
and is caused by null mutations that lead to the loss of the normal copy of the mutated gene.  
In this context, gene therapy represents a promising therapeutic approach, thanks to which the gene 
that is affected by the mutation can be replaced.  
To date more than 30 genes and loci have been associated with arRP (RetNet 
database; https://sph.uth.edu/retnet/sum-dis.htm), but the sum of their frequencies does not explain 
more than a third of the arRP cases, since the majority of them contribute to less than 1% of cases 
and only few are responsible for more than 10% of cases [1]. However, most of these data have 
been obtained from European and North American countries, and studies in different populations 
have shown that the genetic component of the disease could not be the same [2]. 
Recent advances in sequencing techniques and lower costs allow nowadays analyzing many genes 
simultaneously. Exome sequencing has proved effective in identifying the genetic cause of several 
rare Mendelian disorders, including RP, by interrogating only the coding fraction of the genome, 
which is roughly 1% of the entire genome.  
However, it is becoming increasingly evident that some of the missing causative mutations may 
reside in non-coding regions of the genome, such as intronic regions [3-6] or can be structural 
rearrangements, such as large deletions or insertions [7-8], which are very challenging to be 
identified by conventional screening methods and even by exome sequencing.  
Whole genome sequencing (WGS) overcomes this obstacle, covering all the coding and non-coding 
areas of the genome and having the ability to detect large structural rearrangements. 
In this study we used whole genome sequencing to identify disease-causing mutations in 16 
unrelated individuals with different ethnicities, who were all diagnosed with recessive retinitis 
pigmentosa. 
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Methods 
Patients and controls 
Our research protocol was designed in compliance with the Declaration of Helsinki and approved 
by the Institutional Review Boards of the University of Lausanne, the Massachusetts Eye and Ear 
and Harvard Medical School, and of the Nagoya University School of Medicine. Written informed 
consent for providing medical information and blood samples was obtained from each participant. 
Leukocyte DNA was obtained from 4 patients from the Berman-Gund Laboratory, Massachusetts 
Eye and Ear. These patients had a family history indicative of recessive form of inheritance and 
they were previously screened for a variety of known RP genes.  
Leukocyte DNA was also prepared from 12 patients of Japanese ancestry from the Nagoya 
University Hospital. They had RP with no family history (isolate RP) or a family history indicative 
of arRP and were unscreened for known RP gene.  
All patients were subjected to comprehensive clinical examinations including ERG, visual field 
testing, and fundus examination and were judged to have a non-syndromic form of the disease 
based on the lack of significant non-ocular medical history and symptoms. 
Genomes from 69 healthy individuals, sequenced with the same methodology at Complete 
Genomics Inc. and publicly available (http://www.completegenomics.com/), together with DNA of 
95 healthy Caucasians purchased by the Coriell DNA Repository (http://www.coriell.org/) and of 
95 healthy Japanese provided by the Nagoya University Hospital, were used as controls.  
 
Whole genome sequencing 
Five to seven microgram of high quality DNA was sent to Complete Genomics Inc. (Mountain 
View, CA, USA), where they performed whole genome sequencing based on the technique they 
have been developed [9]. Variant annotation was performed by using dbSNP build 132 and the 
human genome version hg19 (http://hgdownload.cse.ucsc.edu/downloads.html).  
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Analysis of the mapping results 
Complete Genomics provided ready annotated text files for SNPs and small indels, for junctions 
(larger structural rearrangements), for copy number variations, and for mobile-element insertion 
events.  
Perl scripts were developed in-house and used in combination with the “CGA tools” provided by 
Complete Genomics (http://www.completegenomics.com/sequence-data/cgatools/) to help 
analyzing the huge amount of data. 
A total of 157 genes reported to be associated with inherited retinal degenerations either in humans 
or in animal models, or that were shown to be essential for the functioning of the retina, were 
selected for the analysis of variants in known disease-associated genes (Supplementary Table S1).  
 
Homozygosity mapping 
To determine the presence of homozygous genomic regions, likely indicative of being identical by 
descent (IBD), we used about 600,000 high quality SNPs included in the Illumina 660W chip 
(Illumina Inc., San Diego, CA, USA) and run the autozygosity analysis with the 
HomozygosityMapper web-based tool (http://www.homozygositymapper.org/). 
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Results 
General considerations about whole genome sequencing 
In the 16 unrelated individuals we observed an average coverage for the sequencing of the whole 
genome of 97% and for the sequencing of the whole exome of 98%. The average sequencing depth 
was 50X, with 98% of the reads being sequenced with depth >10X.  
We obtained an average of three to four million SNPs per genome, of which 4% were novel 
variants, and this data did not differ much between Japanese and North American individuals.  
Specificity and sensitivity of the technique were tested by sequencing with Sanger method the calls 
that were flagged with an indicator of good quality; about 70% of the high-quality calls were indeed 
true variants.  
 
Homozygosity mapping 
Analysis of autozygosity was performed for each genome in order to check for parental 
consanguinity. Using genotypes of known polymorphic variants listed in the 660W Illumina chip 
we looked for intervals with high level of homozygosity (at least 500 consecutive SNP markers).  
Only two Japanese and one North American individual from our cohort presented IBD regions, 
which were however not overlapping. 
 
Sequence analysis of known RP genes 
As a first analytical step, we looked for changes that could severely impair protein function, present 
either in a homozygous or compound heterozygous state, since we were assuming a recessive mode 
of inheritance. Variants annotated in dbSNP with a frequency ≥ 2% were excluded from the list of 
likely pathogenic variants. If two strong variants were not present in the same gene, we analyzed the 
information deriving from discordant mate pair sequences, indicative of large structural 
rearrangements. These data are usually reporting changes in the range of few hundred bases that 
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could affect coding regions of the genome. This type of analysis was found to be highly sensitive to 
the quality of the DNA, in particular if the DNA was collected a long time before the sequencing. 
Missense changes were prioritized by running prediction algorithms for pathogenicity (PolyPhen-2, 
http://genetics.bwh.harvard.edu/pph2/, and SIFT, http://sift.jcvi.org/) and by looking at the amino 
acidic conservation (HomoloGene, http://www.ncbi.nlm.nih.gov/homologene). 
With the list of candidate variations we performed a literature search to check whether the variants 
had been already associated with arRP or other allied diseases, and to exclude variants that had been 
reported as non-pathogenic. The final list with the disease-causing variations we found is reported 
in Table 1. All variants have been confirmed by Sanger sequencing. 
We found 2 clearly pathogenic changes in 7 out of 16 individuals (2 North Americans and 5 
Japanese), in 6 different genes.  
Patient 003-146 is a compound heterozygous for a frameshift mutation (p.Q465fsX505) and a large 
deletion in the gene SPATA7. The same frameshift has been previously reported in a French 
Canadian individual with juvenile retinitis pigmentosa [10]. Through the analysis of discordant 
mate pair sequences we identified a 1’313 bp deletion between intron 7 and exon 8 of SPATA7, 
which is expected to affect splicing. This structural rearrangement is novel and was not found 
neither in the control genomes nor in a cohort of 95 healthy Caucasians.  
121-847 is a North American patient with Jewish ancestry, which was found to have an IBD region 
on chromosome 6. This patient indeed harbours a homozygous 353-bp Alu-element insertion in 
exon 9 of male germ cell-associated kinase (MAK), which has been associated with recessive 
retinitis pigmentosa in individuals with Jewish ancestry [11].  
Another IBD region was identified on chromosome 6 in patient R6, who was found to have a 
homozygous missense mutation (p.R515W) in RPE65, which was previously reported in a Japanese 
patient with recessive RP [12].   
In two Japanese patients (R25 and R41) we identified compound heterozygous variants in EYS. 
Both individuals share the same frameshift mutation (p.S1653KfsX2) that is thought to be one of 
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the major causes of arRP in the Japanese population [13]. Together with the frameshift mutation, 
patient R25 carries a nonsense variant (p.Y2935*) that was reported as a founder mutation in the 
Japanese population [13]. In patient R41 we identified as a second variant in EYS a novel frameshift 
(p.NS3062fs), which affects the same amino acidic residue that was found to be mutated in a 
Spanish patient with arRP [14]. 
Patient R51 harbours a known frameshift mutation (p.EG801GEfs) in RPGR [15], which is 
causative of X-linked RP. In this case then the mode of inheritance of the disease is not recessive 
but X-linked. 
In patient R26 we found a heterozygous novel frameshift variant (p.Q411fs) in the gene PRPF31, 
which is linked to an autosomal dominant form of the disease. The change was not present neither 
in the control genomes nor in a cohort of 95 healthy Japanese individuals. Cosegregation analysis in 
the family showed a complete concordance between the genotype and the phenotype for the 
mutation (Figure 1). The mode of inheritance in this family seems to be autosomal dominant with 
incomplete penetrance, although this can not be proven because the father of the proband, who was 
diagnosed as healthy, died and thus we could not test if he is a carrier of the mutation (Figure 1).  
One of the North American patients (003-102) carries two variants, a frameshift (p.M1731fs) and a 
missense (p.G546V), in the gene USH2A. Both variants are novel, but the missense variant targets 
an amino acidic residue where a polymorphism, which causes a different amino acidic change, has 
been reported (rs142282413). The in silico prediction for the pathogenicity of the missense variant 
suggests that it is probably pathogenic. The patient reported hearing impairment, but there is no 
DNA of other family members available, therefore without the cosegregation analysis is impossible 
to determine with certainty whether this two variants in USH2A could be the cause of the disease. 
Finally, one of the Japanese patients (R10) had a heterozygous missense variant (p.S343N) in the 
RHO gene. The variant is novel and was not found neither in the control genomes nor in 95 healthy 
Japanese individuals. Cosegregation analysis in the family, however, revealed the presence of this 
variant also in the unaffected relatives, suggesting that it is a polymorphism in the Japanese 
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population (Figure 2). However, what emerged from the revision of the pedigree is that the way of 
inheritance of the disease is dominant and not recessive (Figure 2). 
Discussion 
Massively parallel sequencing proved to be an effective approach to identify the aetiology of many 
Mendelian disorders, including retinitis pigmentosa.  
The most commonly used strategies for the identification of disease-causing genes in Mendelian 
diseases have been either sequencing many individuals with the same phenotype, or sequencing 
several members of the same family.  
Our approach was different, since we sequenced unrelated individuals with different ethnicities but 
the same phenotype, in order to evaluate if whole genome sequencing could be an effective strategy 
to reveal the causes of such a genetically heterogeneous disease.  
The most obvious benefit of such an approach compared to the conventional screening methods and 
to whole exome sequencing seemed to be the identification of large structural rearrangements, 
whose junctions are located deeply in intronic regions. 
In our study we identified a large deletion (> 1 kb) encompassing intron 7 and exon 8 of SPATA7. 
One of the junctions was found to be very distant from the coding sequence of the gene, so it would 
have been very difficult to detect it without using whole genome sequencing. 
Looking only at variants in genes that have been previously associated with inherited retinal 
degenerations we identified the cause of disease in about 45% of the individuals in our cohort.  
In the majority of individuals where we were able to identify the disease-causing gene at least one 
of the two variants (in case of compound heterozygosity) had a strong impact at the protein level. 
Aetiology of retinitis pigmentosa in the Japanese population has not been much investigated, but 
what emerged so far is that causative RP genes in the European and North American populations 
can explain only a small percentage of RP cases in Japan. An exception is EYS that has been 
reported as a major cause of arRP in the Japanese population [13]. Among the Japanese individuals 
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in our cohort we found two that harbour mutations in EYS; interestingly, both of them have one of 
the founder mutations that have been identified in the Japanese population (p.S1653KfsX2) [13].  
Despite all patients had been diagnosed with autosomal recessive retinitis pigmentosa, two Japanese 
individuals resulted to have a dominant way of inheritance instead. In at least one of them it was 
possible, even starting from nearly 4 million variants, to identify the heterozygous change that is 
responsible for the disease.  
Whole genome sequencing proved also to be effective in identifying a few hundred bp Alu-element 
insertion in MAK, which was previously reported in a patient with recessive RP [11]. In the “mobile 
element insertion events” file information on whether the rearrangements occur in coding or non-
coding genomic regions are provided. This is a fast and easy way to go through this class of 
variations that would not be otherwise taken into account by standard screening methods.  
We can hypothesize that part of the unsolved cases in our cohort may be explained by mutations in 
genes that have not yet been associated with the disease. Other explanations may also be that the 
disease-causing variants are structural rearrangements that we failed to detect due to mapping or 
sequencing limitations or less obvious pathogenic changes that may otherwise alter splicing or 
transcription. Oligogenic inheritance should also be considered as a further hypothesis to explain 
the pathogenesis of the disease, since it has been already proven in inherited retinal disorders, like 
digenic inheritance in RP or triallelic inheritance in Bardet-Biedl syndrome [16-17].  
Limitations of whole genome sequencing are represented mainly by the high cost, although it is 
rapidly decreasing, and by the large quantity and high quality of DNA that is required for analysis. 
In addition, a technical limitation is the lack of a pipeline to detect structural variants ranging from 
50 to a few hundred base pairs, which should be implemented in the coming years in order not to 
fail to detect causative variants.  
In conclusion, this approach, starting from a huge amount of genomic variants, has allowed us to 
identify the disease-causing mutation in unrelated individuals with a genetically heterogeneous 
Mendelian disease. 
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Patient 
ID Gene Protein change State Reference Interpretation 
003-102 USH2A M1731fs Het Novel Possibly pathogenic 
  G546V Het Novel  
003-146 SPATA7 Q465fsX505 Het Wang et al. 2009 Pathogenic 
  1’313 bp deletion Het Novel  
003-154     No candidates 
121-847 MAK K433 Hom Tucker et al. 2011 Pathogenic 
R5     No candidates 
R6 RPE65 R515W Hom Kondo et al. 2004 Pathogenic 
R7     No candidates 
R10 RHO S343N Het Novel Non-pathogenic 
R25 EYS S1653KfsX2 Het Hosono et al. 2012 Pathogenic 
  Y2935* Het Iwanami et al. 2012  
R26 PRPF31 Q411fs Het Novel Pathogenic 
R28     No candidates 
R31     No candidates 
R35     No candidates 
R38     No candidates 
R41 EYS S1653KfsX2 Het Hosono et al. 2012 Pathogenic 
  NS3062fs Het 
Same amino acidic position of 
another variant reported  
by Barragan et al. 2010 
 
R51 RPGR EG801GEfs Hemi Vervoort et al. 2000 Pathogenic 
 
 
Table 1. Summary of non-polymorphic variants found in known arRP genes. North American 
patients are highlighted in yellow; Japanese patients are highlighted in blue. Abbreviations: Het, 
heterozygous; Hom, homozygous; Hemi, hemizygous.  
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Figure 1. Cosegregation analysis in the family of proband R26. Arrows indicate the 
individuals for which it was possible to perform the analysis. The red arrow indicates 
the proband. 
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Figure 2. Cosegregation analysis in the family of proband R10.  
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ABCA4 
ABHD12 
ADAM9 
AGTPBP1 
AHI1 
AIPL1 
ALDH3A2 
ALMS1 
ARL3 
ARL6 
ATP6 
ATXN2 
BBS1 
BBS10 
BBS12 
BBS2 
BBS4 
BBS5 
BBS7 
BBS9 
C10ORF2 
C2orf71 
C8orf37 
CA4 
CABP4 
CACNA1F 
CC2D2A 
CCDC66 
CCL2 
CDH23 
CEP290 
CERKL 
CHM 
CLN3 
CLN5 
CLN6 
CLN8 
CLRN1 
CNGA1 
CNGB1 
CNNM4 
CRB1 
CRX 
CTNS 
CUL3 
CX3CL1 
CYP4V2 
DFNB31 
DHDDS 
ELOVL4 
ERCC2 
ERCC6 
 
ERCC8 
EYS 
FAM57B 
FAM161A 
FAM169A 
FLVCR1 
GNAT1 
GNPTG 
GPR98 
GPR179 
GRK1 
GUCA1A 
GUCA1B 
GUCY2D 
HARS 
HMX1 
IDH3B 
IMPDH1 
IMPG2 
INPP5E 
INVS 
IQCB1 
KCNV2 
KIF11 
KLHL7 
LCA5 
LRAT 
LZTFL1 
MAK 
MERTK 
MFN2 
MFRP 
MKKS 
MPDZ 
MTTP 
MYO7A 
NPHP1 
NPHP3 
NR2E3 
NRL 
NYX 
OAT 
OFD1 
PCDH15 
PCDH21 
PDE6A 
PDE6B 
PDE6G 
PEX1 
PEX12 
PEX26 
PEX5 
 
 
PEX7 
PHYH 
PLA265 
PRCD 
PROM1 
PRPF3 
PRPF31 
PRPF6 
PRPF8 
PRPH2 
PXMP3 
RBP3 
RBP4 
RD3 
RDH12 
RGR 
RHO 
RIMS1 
RLBP1 
ROM1 
RP1 
RP2 RP9 
RPE65 
RPGR 
RPGRIP1 
RPGRIP1L 
SAG 
SDCCA68 
SEMA4A 
SLC4A3 
SNRNP200 
SPATA7 
TMEM216 
TMEM237 
TOPORS 
TPP1 
TRIM32 
TRIM37 
TRNH 
TRNL1 
TRNP 
TRNS2 
TRPM1 
TTC8 
TTPA 
TULP1 
UNC119 
USH1C 
USH1G 
USH2A 
WDR19 
ZNF513 
 
 
Supplementary Table S1. List of 157 genes that we used for our analysis.
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 Chapter 6 
 
 
 
 
Clinicopathologic and molecular analysis of a choroidal pigmented schwannoma 
in the context of a PTEN hamartoma tumor syndrome 
 
 
Published in Ophthalmology 119(4):857-64, 2012 
 
 
The aim of this project was to characterize the clinical and molecular nature of a rare ocular tumor, 
described for the first time in the choroid of a patient diagnosed with PTEN hamartoma tumor 
syndrome.  
 
The project was a collaboration with Dr. Alexandre P. Moulin (Ophthalmology, Jules Gonin Eye 
Hospital, Lausanne, Switzerland). 
 
This project led to the clinical description of a rare tumor and to the discovery that at the molecular 
level the tumor presented a unique combination of reduction of PTEN and absence of NF2 
expression, two ubiquitously expressed tumor-suppressor genes that had never been proven to 
contribute together to tumorigenesis.  
 
In this study I performed the molecular genetic analyses and I participated in the article writing.  
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Table 1. 
Primers for polymerase chain reaction amplification of PTEN exons. 
 
 
Targeted 
Exon Sense primer Antisense primer 
Annealing 
temperature 
(°C) 
Amplification 
product (bp) 
Exon 1 
 
GCAGCTTCTGCCATCTCTCT 
 
CATCCGTCTACTCCCACGTT 
 
60 200 
Exon 2 
 
GTTTGATTGCTGCATATTTCAGAT 
 
TGAAATAGAAAATCAAAGCATTCT 
 
58 163 
Exon 3 
 
TTAATGGTGGCTTTTTGTTTGT 
 
CTCTACCTCACTCTAACAAGCAGA 
 
58 168 
Exon 4 
 
CTAAGTGCAAAAGATAACTTTATATCA 
 
ACAACATAGTACAGTACATTCATACCTAC 
 
54 120 
Exon 5 
(I°) 
 
CTTATTCTGAGGTTATCTTTTTACCACA 
 
 
ACACCAGTTCGTCCCTTTCCA 
 
60 174 
Exon 5 
(II°) 
 
GCTGGAAAGGGACGAACTGG 
 
 
TCCAGGAAGAGGAAAGGAAAAAC 
 
65 155 
Exon 6 
 
TGGCTACGACCCAGTTACCATAGCA 
 
 
TGCAAGTTCCGCCACTGAACA 
 
54 235 
Exon 7 
(I°) 
 
TACTGGTATGTATTTAACCATGCAG 
 
 
ACACACAGGTAACGGCTGAG 
 
58 139 
Exon 7 
(II°) 
 
AGCCGTTACCTGTGTGTGGTGA 
 
 
TGCCAGAGTAAGCAAAACACCTGC 
 
65 200 
Exon 8 
(I°) 
 
GTCATTTCATTTCTTTTTCTTTTCT 
 
 
CTGCACGCTCTATACTGCAAATG 
 
60 169 
Exon 8 
(II°) 
 
ACCAGGACCAGAGGAAACCT 
 
 
ACAAGTCAACAACCCCCACAA 
 
60 227 
Exon 9 
(I°) 
AGATGAGTCATATTTGTGGG ATGATCAGGTTCATTGTCAC 54 148 
Exon 9 
(II°) CATTCAACTTCTGTAACAC ATGGTGTTTTATCCCTCTTG 51 165 
 
 
bp: base pair. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
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Table 2. 
Redesigned primers for polymerase chain reaction amplification of NF2 exons. 
 
 
Targeted 
Exon Sense primer Antisense primer 
Annealing 
temperature (°C) 
Amplification 
product (bp) 
Exon 2 
 
TGTCCTTCCCCATTGGTTTG 
 
CAGTTTCATCGAGTTCTAGCC 
 
60 180 
Exon 3 
 
GGGTAGCACAGGAGGAAGTG 
 
AACTCTGCAACCACTCCTGG 
 
60 245 
Exon 4 
 
ATCAGCCTACACACCTCACT 
 
ACCCAAATTAACGCCCAGGA 
 
60 194 
Exon 5  
 
AGAATCTCAATCGCCTGCTC 
 
 
GATCCCACACTGTTTACTGG 
 
58 254 
Exon 6 
 
TGTGACTATCTCCCTGGGT 
 
 
CCAGCTCTCCCCTTTTCTT 
 
58 358 
 
Exon 11 
 
CTTTGGGCCCTTGTGGCAC - 60 268 
 
Exon 12 
 
CCATCTCAGTGTTCAAGGCA CAGTCACCATCAGCCAAGGA 60 448 
 
Exon 14 
 
GTGCCCATTGCCTCTGTG - 60 253 
 
 
 
 
 
 
 
Table 3. 
Primers for PTEN, NF2 and 18S cDNA amplification. 
 
 
 
 
 
 
Targeted 
sequence Sense primer Antisense primer 
Annealing 
temperature (°C) 
Amplification 
product (bp) 
 
PTEN 
 
TGAAGGCGTATACAGGAACAAT CGGTGTCATAATGTCTTTCAGC 60 110 
 
NF2 
 
CGCCCATGAACCCAATTC GGCTGTCACCAATGAGGTTGA 60 70 
 
18S  
 
CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT 60 187 
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 Chapter 7 
 
 
 
Discussion 
 
The focus of my thesis was to better understand the molecular mechanisms that are involved in the 
pathogenesis of retinitis pigmentosa (RP), one of the most common forms of inherited retinal 
degeneration. The most interesting aspect of this disease is certainly its wide heterogeneity both at 
the clinical and genetic level, which is not only due to different mutations in different genes, but 
also to different effects of the same mutation in different individuals, sometimes even within the 
same family.  
In families with PRPF31 mutations we often observe the presence of asymptomatic individuals 
who, despite being carriers of the mutation, do not develop any symptoms of the disease, even at a 
later age [1-4]. The vast majority of PRPF31 mutations reported to date result in the degradation of 
the mutated allele by nonsense-mediated mRNA decay, suggesting that haploinsufficiency can 
explain the pathophysiological mechanism of the disease [5-8]. Asymptomatic individuals in 
PRPF31 families have a higher amount of PRPF31 wild type transcript with respect to their 
affected siblings, suggesting that this could prevent them from developing symptoms [9-10].  
Penetrance of PRPF31 mutations is known to be modulated by at least two penetrance factors, 
located on chromosome 19 in proximity of PRPF31 itself and on chromosome 14, respectively [11-
12]. They are most likely diffusible factors that act simultaneously on the transcription of both 
PRPF31 alleles [12]. 
We identified the modifier of PRPF31 penetrance located on chromosome 19q13.4 in a large family 
with several affected and asymptomatic sibships. The gene, CNOT3, has an inverse trend of 
expression with respect to that of PRPF31, being expressed poorly in asymptomatic compared to 
affected members of the same family [13]. Inhibition of CNOT3 expression in vitro leads to 
increased PRPF31 expression, suggesting that CNOT3 may behave as a negative regulator of 
PRPF31 expression [13]. Transcriptional regulation of PRPF31 expression is mediated by the 
direct binding of CNOT3 to the experimentally validated PRPF31 promoter sequence [13]. 
Furthermore, polymorphic alleles on CNOT3 genomic region (i.e. rs4806718) can explain the 
manifestation of the disease in three families with different PRPF31 mutations, even if the 
association between rs4806718’s C allele and the disease is not perfect [13] (Venturini, unpublished 
results). The not perfect genotype-phenotype correlation for the alleles on chromosome 19 was 
expected, since previous studies showed that they could not explain the manifestation of the disease 
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in all siblings of PRPF31 families [11], and at least another factor on chromosome 14 should be 
involved in the regulation of PRPF31 penetrance [12].   
A link between rs4806718 alleles and CNOT3 differential expression needs still to be proven with 
some functional evidences. However, given the presence of this SNP in a non-coding genomic 
region, it will not be straightforward. 
Functional PRPF31 promoter polymorphisms have been also investigated by others, but no 
association could be found to explain the variability in PRPF31 expression [14].  
The most likely scenario is that PRPF31 expression level would be determined by several 
functional polymorphisms within the 19q13.4 region that may act in a cooperative manner. 
CNOT3 involvement in the modulation of the penetrance of PRPF31 mutations does not seem to be 
a mechanism refined to a single family, but to at least two other families with different PRPF31 
mutations (Venturini, unpublished results). 
In all families we studied asymptomatic individuals have an increased expression not only of 
PRPF31, but also of all other splicing factors that we tested (Venturini, unpublished results). This is 
in agreement with the observation that CNOT3 inhibition in vitro leads to a tendency of other 
splicing factors to be more highly expressed, although the most obvious effect is on PRPF31 
expression (Venturini, unpublished results). Our hypothesis is that there may be a direct effect of 
CNOT3 only on PRPF31 expression and what we observe at the level of other splicing factors is a 
stochiometric response to the increased expression of one of the spliceosome components. 
Overall, PRPF31-linked retinitis pigmentosa seems to be more complex than expected, since 
clinical manifestations would depend on several genetic interactions that would modulate the effect 
of PRPF31 mutation. 
Much remains to be assessed to fully understand the mechanisms that regulate PRPF31 penetrance; 
our data show that CNOT3 is the modifier on chromosome 19 of PRPF31 penetrance, but other 
modifiers, including the one that lies on chromosome 14, should be considered.  
Despite penetrance being a well-known concept in genetics, not much has been discovered about 
the molecular mechanisms that underlie incomplete penetrance in inherited human diseases; our 
research is one of the few examples in which a penetrance factor could be identified and its 
mechanism of action characterized. 
Since haploinsufficiency is the cause of the disease in most PRPF31 families, restoring the normal 
level of PRPF31 transcript by subretinal injection of PRPF31 wild-type cDNA could represent a 
promising therapeutic approach. Although we showed that PRPF31 expression can be increased by 
inhibiting CNOT3 expression, little has been so far elucidated on the overall effects of CNOT3 
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inhibition in human cells and tissues, thus further studies are required before thinking of a possible 
CNOT3-targeted therapeutic approach. 
 
Following the same rationale of investigating molecular mechanisms that are responsible for 
clinical and genetic heterogeneity of retinitis pigmentosa, I have been studying a recessive form of 
the disease, where mutations in the same gene give rise to variable clinical manifestations. 
FAM161A mutations were recently identified in patients with recessive retinitis pigmentosa [15-16]. 
All reported mutations lead to loss-of-function of the encoded protein, but clinical manifestations of 
the disease may vary widely depending on the mutation. Patients with FAM161A mutations have 
been described as having a late-onset form of RP, described in a German cohort of patients [16], 
and an early-onset manifestation of the disease in Israeli and Palestinian individuals [15].   
Prevalence of FAM161A-linked recessive RP is also different in individuals from different 
ethnicities, being in the German population comparable to the prevalence of most arRP genes [16], 
while, in the Israeli and Palestinian populations, FAM161A is the most frequently mutated gene in 
patients with arRP [15]. 
In a large cohort of North American arRP patients with mixed ethnicity, we found a prevalence of 
FAM161A mutations similar to that detected in Germany (<2%). Interestingly, one variant that had 
previously been reported as a founder mutation in the Israeli and Palestinian population 
(p.T452Sfx3) [15] is the only mutation that was found in patients from our cohort, and all except 
one of them reported Jewish ancestry.  
Furthermore, from our study it emerged that there are many rare variants in FAM161A, which are 
reported in dbSNP with a minor allele frequency of less than 1%, that are frequently found in 
patients but not in controls, whose functional meaning is uncertain. In particular one of those 
variants (p.L378R), which is predicted to have a deleterious effect on the encoded protein and is 
affecting a highly conserved amino acid residue, has been frequently found in a heterozygous state 
in arRP patients both from our cohort and from the German one. 
Growing evidences are highlighting that retinitis pigmentosa could be considered as an oligogenic 
disease in which several variants summed to the disease-causing mutation can modulate the 
phenotype of the disease. It would be interesting to see whether FAM161A p.L378R variant may 
behave as a modifier of recessive forms of retinitis pigmentosa; to investigate this hypothesis we are 
performing whole exome sequencing of all patients that harbour this variant in order to see if it 
would be frequently associated with other variants and if the phenotype within a family may be 
influenced by the presence of this variant. 
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In the last years there have been a rapid decrease in the cost of massively parallel sequencing 
together with an improvement of sequencing technologies, which enable today to interrogate the 
entire exome and even individual's genomes.  
Exome sequencing is the most commonly used approach to unravel the genetic causes of inherited 
Mendelian diseases, as the costs of sequencing are contained and the information obtained 
correspond only to the coding fraction of the genome that is more easily interpretable.  
On the other hand, it is increasingly evident in diseases such as retinitis pigmentosa that individuals 
in which we were unable to identify the genetic cause of the disease with standard diagnostic 
techniques and even with exome sequencing may harbour large structural rearrangements and/or 
variations in non-coding sequences of the genome. 
Whole genome sequencing has the advantage, with respect to whole exome sequencing, of 
providing an overview of all variants and structural rearrangements in coding and non-coding 
portions of the genome, leading, nevertheless, to a huge increase in the amount of data to analyze, 
whose interpretability is not always easy. 
Our experience with whole genome sequencing of unrelated patients with recessive retinitis 
pigmentosa shows that this approach can be effective in identifying disease-causing variants that 
might have otherwise failed to be detected with other screening methods (i.e. structural 
rearrangements larger than 1 kb) and that, starting from millions of variants per individual, we can 
get to a short list of candidates to be analysed. 
The final goal, after having potentially identified a disease-causing variant, would be to prove at the 
functional level that the change is indeed responsible for the phenotype.  
To test variations in genes with a tissue-specific expression it would be ideal to have access to the 
tissue where the disease develops. To date, blood is the most commonly used tissue from RP 
patients, because obviously we cannot have access to the retina of patients who are still alive.  
The generation of induced pluripotent stem cells (iPSCs) from somatic human cells has opened the 
possibility to differentiate them into a wide range of tissue-specific lineages. Fibroblast-derived 
iPSCs have been already differentiated into photoreceptor and RPE cells and iPSCs have been also 
obtained from EBV-immortalised B-lymphocytes, or alternatively CD34+ blood cells [17-20]. 
A successful example of the advantage of differentiating retinal cells from fibroblast-derived iPSCs 
to functionally prove the effect of a mutation is represented by an Alu-element insertion in the gene 
MAK, which was found in a patient with recessive retinitis pigmentosa. In the retinal-like cells the 
mutation was in fact proven to prevent a retina-specific isoform to be expressed [21].  
The same mutation, which was first identified in a patient with Jewish ancestry [21], was lately 
found in several other individuals with recessive RP who reported Jewish origin [22] (Venturini, 
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unpublished results); interestingly, all the ones we identified in our cohort share a common 
haplotype, suggestive of a founder mutation in the Jewish population. Since the majority of North 
American Jews belong to the Ashkenazi subpopulation, we are aiming to identify an Ashkenazi-
specific haplotype in patients harbouring the mutation. If we could establish with certainty that the 
mutation is present only in Ashkenazi Jews with such a high prevalence this would be of clinical 
relevance to implement Ashkenazi carrier screening panels.  
 
Finally, as a side project, I have been studying a rare form of cancer developed in the choroid of a 
young girl affected by PTEN hamartoma tumor syndrome, a genetic disorder caused by germline 
mutations of the tumor suppressor gene PTEN. For the first time we reported a choroidal tumor 
among the clinical manifestations of PHTS, which was made by glial cells of the peripheral nervous 
tissue [23]. 
Furthermore, this tumor showed a unique combination of PTEN reduction and NF2 absence [23], 
which is interesting considering that both proteins have been shown to be involved in the regulation 
of mTOR signalling pathway in human cancers [24]. This study has therefore highlighted the 
heterogeneity of this choroidal tumor, showing that genetic and/or epigenetic alterations in different 
genes may contribute to the tumor development and growth. 
 
 
Overall, the work done during my thesis has helped to shed light on new molecular mechanisms 
that are involved in the pathogenesis of a common form of inherited retinal degeneration and of a 
rare tumor of the choroid and opens the perspective for further studies with the ultimate goal of 
developing molecular-targeted therapies. 
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Abbreviations 
 
 
 
Ab   Antibody 
ACTB   Beta-actin 
adRP   Autosomal dominant retinitis pigmentosa 
AF  Affected individuals 
AJ   Ashkenazi Jews  
AMD   Age-related macular degeneration 
ARPE-19   Human retinal pigment epithelial cell line  
arRP  Autosomal recessive retinitis pigmentosa 
AS   Asymptomatic individuals 
BCA  Bicinchoninic acid  
bFGF   Basic fibroblast-derived growth factor    
bp   Base pair 
BRR2   Small nuclear ribonucleoprotein 200kDa (U5) 
BSA   Bovine serum albumin 
cDNA   Complementary DNA 
CEPH   Centre d'etude du polymorphisme humain 
cGMP   Cyclic guanosine monophosphate 
ChIP  Chromatin immunoprecipitation 
CLRN1  Clarin-1  
CNOT2 CCR4-NOT Transcription Complex, Subunit 2 
CNOT3  CCR4-NOT Transcription Complex, Subunit 3 
CNTF   Ciliary neurotrophic factor  
CRX   Cone-rod homeobox protein 
DA   Dark adaptation 
dbSNP   Short genetic variations database 
del   Deletion 
DHA  Docosahezaenoic acid 
DHDDS Dehydrodolichyl diphosphate synthase 
DHFR   Dihydrofolate reductase 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTP   Deoxyribonucleotide triphosphate 
e.g. Exempli gratia 
EBV   Epstein Barr virus  
EDTA   Ethylenediaminetetraacetic acid 
ERG  Electroretinogram 
EST   Expressed sequence tag 
EYS   Eyes shut homolog (Drosophila) 
FAM161A   Family with sequence similarity 161, member A 
FECH   Ferrochelatase 
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FFPE   Formalin-fixed paraffin-embedded  
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase  
GCL   Ganglion cell layer 
HRP   Horseradish peroxidase  
hrs Hours 
Hz   Hertz 
i.e. Id est 
IBD   Identical by descent 
IgG Immunoglobulin G 
ILT7   Leukocyte immunoglobulin-like receptor subfamily A member 4 
INL   Inner nuclear layer 
IP   Immunoprecipitation 
IPL   Inner plexiform layer 
ipRGCs   Intrinsically photosensitive retinal ganglion cells 
iPSCs  Induced pluripotent stem cells  
IRB   Institutional review board 
IU   International units 
kb   Kilobase 
kDa Kilodalton 
LCA   Leber congenital amaurosis 
LCL   Lymphoblastoid cell line 
LCR   Leukocyte receptor cluster 
LENG1   Leukocyte receptor cluster, member 1 
LILRB3  Leukocyte immunoglobulin-like receptor, subfamily B, member 3 
LOH   Loss of heterozygosity 
MAF   Minor allele frequency 
MAK   Male germ cell-associated kinase 
Mb  Megabase 
MBOAT7 Membrane bound O-acyltransferase domain containing 7 
MDH1   Malate dehydrogenase 1, NAD  
miRNA   microRNA 
ml  Milliliter  
mRNA   Messenger RNA 
mTOR   Mammalian target of rapamycin 
mV   Millivolt 
µl   Microliter 
µM   Micromolar 
µV   Microvolt 
NA   Not available 
NALP2   NLR family, pyrin domain containing 2 
NCBI   National center for biotechnology information 
NDUFA3   NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3 
NF2   Neurofibromin 2 
NFL   Nerve fiber layer 
ng   Nanogram 
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NGS   Next generation sequencing  
nM   Nanomolar 
NMD   Nonsense mediated mRNA decay 
nmol Nanomole 
NRL   Neural retina-specific leucine zipper protein 
OD   Oculus dexter 
ONL   Outer nuclear layer 
OPL   Outer plexiform layer 
OS   Oculus sinister 
PAP-1   Retinitis pigmentosa 9 (autosomal dominant) 
PBS   Phosphate buffered saline 
PCDH15   Protocadherin-15 
PCR   Polymerase chain reaction 
PHTS   PTEN hamartoma tumor syndrome 
pmol   Picomole 
pre-mRNA  Precursor mRNA 
PRPF3   PRP3 pre-mRNA processing factor 3 homolog (S. Cerevisiae)  
PRPF31   PRP31 pre-mRNA processing factor 31 homolog (S. Cerevisiae) 
PRPF6  PRP6 pre-mRNA processing factor 6 homolog (S. Cerevisiae)  
PRPF8   PRP8 pre-mRNA processing factor 8 homolog (S. Cerevisiae) 
PTEN   Phosphatase and tensin homolog 
qPCR   Quantitative real time polymerase chain reaction 
RACE   Rapid amplification of cDNA ends  
RDS   Peripherin 
RetNet   Retinal information network 
RHO Rhodopsin 
RIPA  Radio immuno precipitation assay  
RNA  Ribonucleic acid 
RNAi  RNA interference 
RNase  Ribonuclease   
ROM1  Rod outer segment membrane protein 1 
RP   Retinitis pigmentosa 
RP1   Retinitis Pigmentosa 1 (Autosomal Dominant) 
RPE   Retinal pigment epithelium 
RPE65   Retinal pigment epithelium-specific 65 kDa protein 
RPGR   X-linked retinitis pigmentosa GTPase regulator 
RPMI   Roswell Park Memorial Institute 
RPS9   40S ribosomal protein S9 
RT-PCR   Reverse transcription polymerase chain reaction 
SDS-PAGE  Sodium dodecyl sulphate - polyacrylamide gel electrophoresis 
siRNA   Small interfering RNA  
SNP   Single-nucleotide polymorphism 
snRNP   Small nuclear ribonuclear particles  
SPATA7   Spermatogenesis associated 7 
SPTA1   Spectrin 
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TFPT   TCF3 (E2A) Fusion Partner (In Childhood Leukemia) 
TBS   Tris-buffered saline 
TE   Tris-EDTA 
TSEN34   tRNA splicing endonuclease 34 homolog (S. Cerevisiae) 
U snRNA   Small nuclear uridine-rich RNA 
U.S.   United States 
USH2A  Usherin 
UTR   Untranslated region 
WES   Whole exome sequencing 
WGS   Whole genome sequencing 
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